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Abstract 
Since the discovery and use of antibiotic compounds in the early 20th century, an increasing amount 
of bacteria have evolved resistance. The problem with resistance leads to the discovery of many new 
compounds, but from the 80’s and onwards there has been a discovery void. This has turned scientist 
towards new antibiotic strategies  to investigate antimicrobial peptides (AMP), so that they could be 
applied medically. One of the hurdles in this process is knowledge on their molecular structure and 
the mode of action. In this report we shed new light on the structure and function of OP-145, an 
engineered AMP derived from the LL-37 sequence observed in the human immune system. 
The crystallization of OP-145 for structural studies did not yield any usable results, but indications 
of which conditions to avoid in further crystallization efforts have been gathered. The growth 
inhibition experiment running for a course of 4 hours on the bacteria E. coli and B. subtilis with the 
antimicrobial peptides compared with traditional antibiotics, shed some light on their effectiveness 
and mode of action. The conditions under which the antibiotics work is crucial for their effect and so 
is the structure related to effectiveness of their mode of action. LL-37 showed significant results in 
halting E.coli growth at a concentration of 6.7 µM, while it and OP-145 had a surprising significant 
growth enhancing effect on B. subtilis. OP-145 did not suppress bacterial cell growth at any of the 
used concentrations (2.5 µM to 19.7 µM) which was also discovered for the lysozyme at 
concentrations (1.8 µM to 14 µM for B. subtilis and 3.5 µM to 28 µM for E. coli). The effort to check 
for a synergistic effect between vancomycin and either LL-37 or OP-145 did not show the desired 
effect, except in the case of one mixture treatment which delayed the bacteria growth (3.3 µM LL-37 
and 10.8 µM vancomycin). While in the case of B. subtilis it can be suggested that the presence of 
AMPs enhanced the resistance towards the traditional antibiotics possibly by increasing the 
availability of amino acids. 
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Introduction 
History of antibiotics and mechanisms of action 
Antibiotics are chemical substances, which block or interfere with crucial pathways in 
microorganisms thereby killing them or inhibiting their growth (Drlica & Perlin, 2011). The 
discovery of antibiotics has probably been the greatest revolution in medicine in the 20th century 
(Aminov, 2010). In the beginning of the 20th century, the German physician Paul Ehrlich found by 
systematic screening a promising organ arsenic derivative with antimicrobial properties (Ehrlich & 
Hata, 1910; Aminov, 2010). The drug was marketed as Salvarsan and was a great success together 
with the less toxic Neosalvarsan. They became the most frequently prescribed antibiotic drugs until 
the discovery of penicillin. The most famous date in the history of antibiotics is 3rd September 1928 
when Alexander Fleming ‘accidentally’ observed the effects of a penicillin mould, which was 
contaminating bacterial plates when he studied staphylococcus variants. The mould clearly lysed the 
plated bacteria and was later shown to have bacteriolytic and bactericidal effects towards more 
common pathogenic bacteria (Aminov, 2010; Fleming, 1929). 
However, it took another 12 years to find ways to purify penicillin quantities sufficient for clinical 
testing. The procedures described by Howard Florey and Ernst Chain led to the beginning of mass 
production and distribution of penicillin in 1945 (Aminov, 2010, Chain et al., 2005). 
The studies of the first antibiotics such as Salvarsan, Prontosil, and penicillin guided the protocols 
for further drug discovery research. The period between 1945 and 1980 was characterized by the most 
discoveries of new classes of antibiotics, most of which were made in the short time span of 15 years 
up to 1960, see figure 1 (WHO, 2014).  
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Figure 1: Discovery of Antibiotics: A timeline of the discovery of some common antibiotics between 1910-2010, with 
the discovery void shown from 1987 to present day. Dates shown are of reported initial discovery or patent (WHO, 2014). 
The time since the late 1980’s is the so called ‘discovery void’ and from then on the mainstream 
approach to develop new drugs has been the modification of existing antibiotics (Aminov, 2010; 
WHO, 2014). Though the overall history of antibiotics has been quite successful, the evolutionary 
process has resulted in microorganisms developing resistance to certain drugs (WHO, 2014). 
The main application of antibiotics has historically been on human as well as veterinary healthcare 
(WHO, 2014). Antibiotics are also commonly and increasingly used in the food industry to treat 
livestock and prevent the spreading of foodborne pathogens (Jensen, 2001; Sarmah et al., 2006; 
WHO, 2014). They are often administered prophylactically and as enhancers of growth of livestock. 
Only in Denmark in year 1997 over 100.000 kg of antibiotics were used for this purpose (Jensen, 
2001). The fact that these antibiotics often find their way into the environment through manure 
fertilizer and watersheds makes it a major issue for the proliferation of antibiotic resistant bacteria in 
nature (Truszczynski & Pejsak, 2013). 
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On the molecular level, antibiotics work in many different ways, some of which are illustrated in 
figure 2 (Lewis, 2013). For example drugs from the Tetracycline family inhibit protein synthesis by 
preventing the aminoacyl-tRNA from attaching to the 30S subunit of the ribosome. It is very versatile 
since it works against Gram-positive and Gram-negative bacteria as well as several parasites (Chopra 
& Roberts, 2001). This makes it one of the drugs most widely used in livestock (Sarmah et al., 2006). 
Meanwhile other drugs such as chloramphenicol act on the 50S subunit of the ribosome blocking its 
ability to catalyze peptide bond formation (Kostopoulou et al., 2015). Other modes of action include 
interference with synthesis of mRNA and therefore suppression of protein synthesis (e.g. through 
rifampicin) (Reid & Speyer, 1970) as well as blocking cell wall synthesis as it is done by drugs of the 
penicillin family (Yocum et al., 1979).  
 
Figure 2: Modes of action of different antibiotics (Lewis, 2013). The main targets are considered to be the ribosomes, cell 
wall synthesis and DNA gyrase or topoisomerase as these are the most conservative. Many other potential conservative 
targets remain unexploited. 
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Mechanisms of resistance 
Resistance to antimicrobial substances modes of action is often occurring naturally in bacterial 
populations. Resistance to some of the most common antibiotics often arises from enzymatic 
inactivation or degradation of the antibiotic, which can be done by either inactivation or hydrolysis 
of the antibiotic, e.g. hydrolysis of the cyclic amide bond in β-lactam type antibiotics by β-lactamases 
(Davies, 1994; Morin & Gorman, 1982). This kind of enzymatic activity can originate from transfer 
of plasmids coding for this enzyme as is found in the increasing occurrence of the β-lactamases (Bratu 
et al., 2005; Medeiros, 1997).  Resistance can arise from already resistant genes exchanged via 
plasmids or random mutation which normally is a small factor, but in the enormous populations of 
microbes this is very effective (Aminov & Mackie, 2007). In a study of the acceleration of emerging 
resistance made by Zhang and colleagues (2011) it was found that resistance towards ciprofloxacin 
emerged in a colony of initial ca. 100 E. coli cells already after 10 hours. Basically resistance is one 
or several mutations or a change in a pathway rendering the antibiotic ineffective (Aminov & Mackie, 
2007).  
Resistance develops in response to how antimicrobial substances work. For an antibiotic to function 
it is essential that it fulfills at least two requirements: (1) it must be able to recognize the target and 
(2) the concentration in the cell must be high enough for the compound to have the desired effect  
(Martìnez & Baquero, 2014). Preventing the substance from recognizing its target can be achieved 
by mutations directly in the target site or mutations in transporters or activators. By modifying the 
antibiotic, removing it from the cell or limiting the penetration into the cell, a microbe can prevent 
the antimicrobial from existing in sufficient amounts and thereby achieve resistance (Lewis, 2013; 
Martínez & Baquero, 2014). Different types of defensive mechanisms are illustrated in figure 3. 
Resistance mechanisms that use enzymes to target and modify/destroy antibiotics did not arise in 
pathogens, because small mutations in the genes of pathogens would have difficulties enabling an 
enzyme (gene product) to inactivate a foreign substrate. This kind of resistance is more likely to have 
its genetic origin in organisms producing antibiotic substances such as the environmental bacterial 
community (Aminov & Mackie, 2007, Davies, 1994). Benveniste & Davies (1973) discovered that 
specific resistance mechanisms, similar to those of isolated clinical resistant strains, were present in 
actinomycetes implying an evolutionary relation of the bacterial enzymes. However, when the gene 
for modifying enzymes is acquired by the pathogen, mutations in this gene can potentially expand 
the range of antibiotics that can be modified and deactivated by the enzyme (Davies, 1994). Target 
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modification as a source of resistance is the lowering of the affinity of the target enzyme for the 
antibiotic (Spratt, 1994). An example of this could be N6-dimethylation of an adenine residue on 23S 
rRNA by an enzyme encoded by erythromycin resistant bacteria. This causes the lowered affinity for 
this antibiotic along with several other antibiotics, using similar binding sites (Leclercq & Courvalin, 
1991). Also the antibiotic streptomycin, an inhibitor of ribosomal activity, ceases to work when the 
affinity of the ribosome is lowered as genes coding for S12 ribosomal protein or 16S rRNA are 
mutated (Davies, 1994). Resistance as a result of target modification mostly arises when the antibiotic 
in question is not a substrate analog or if it only affects one target and causes a lot of problematic 
multiresistant infections (Davies, 1994; Spratt, 1994). The combination of reduction in uptake 
(decreased permeability), efflux pumps and target mutations are common ways for pathogens to cope 
with antibacterial agents, and efflux pumps are argued to have importance in of multi-resistance 
(Nikaido, 2009). Both specific and multidrug efflux pumps exist, the latter causing multi-resistant 
pathogens. The efflux pumps can also have an additive effect together with other types of resistance. 
Most of the genes encoding the pumps are found on the chromosome (Li & Nikaido, 2009). 
 
Figure 3: Spreading of resistance by horizontal gene transfer or clonal expansion and mechanisms of antibiotic resistance 
including target modification, inactivation or modification of antibiotic, limiting penetration, removal of antibiotic from 
the cell, bypass pathways and overproduction of target (Lewis, 2013). 
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The reduction of a microbial population by an antibiotic can in some cases result in a small resistant 
bacterial population which will then be dominating the entire population. Hence, bacteria with 
resistant genes are being selected for, under antimicrobial influence, thereby pressuring the evolution 
of a population towards resistance. The exchange of resistant genes in a microbial population and 
between populations is amplified by the process of transduction, transformation and conjugation, also 
called horizontal gene transfer (Griffiths et al., 2012). This can occur homo- but also heterologously 
(Aminov & Mackie, 2007). Usually mutations preventing antibiotics from reaching their targets such 
as the modification of the antimicrobial target only spread by the clonal expansion of a bacterial 
colony, but resistance achieved through preventing the amount of antibiotics from being sufficient 
e.g. by modifying the antibiotic, can also be spread by horizontal gene transfer (Martínez & Baquero, 
2014). 
Emergence of resistance 
From the evolutionary understanding of populations, resistance has always been a part of pathogenic 
populations, because the microbes try to adapt and outperform the natural defenses of an infected 
organism. Naturally these defenses are not new to living organisms and date back to pre-eukaryotic 
time (Kobayashi et al., 2007). In the recent human history the literature on antibiotic resistance 
focuses on the relation between use and resistance of antibiotics (Aminov, 2010). Already at the 
beginning of the antibiotic era it was shown that some bacteria could destroy penicillin, but despite 
these findings antibiotics were taken up by the public as a scientific miracle (Abraham & Chain, 
1940).  
It is argued that the extensive use and often misuse of antibacterial drugs in humans and animals has 
favored the selection and the spread of resistant bacteria (WHO, 2014). In the US alone 29 million 
pounds of antibiotics were sold for application in food producing animal farming in 2009 (FDA, 
2009. While the number is hard to compare in US healthcare 258 million prescriptions for antibiotics 
were given in 2010 (Hicks et al., 2013). The fate of antibiotics is not always understood and in many 
cases large amount of the antibiotics end up in the environment. Up to 75% of antibiotics fed to 
animals are not taken up, potentially releasing it to the environment by the use of manure as fertilizer 
(Chee-Sanford et al., 2009). The same authors argue that there is a strong selection pressure on 
bacteria in the gastrointestinal flora which makes it a breeding ground for antimicrobial resistant 
genes. These will eventually end up in the environment where it might spread to other bacteria (Chee-
Sanford et al., 2009, Bennet, 2008). This overuse has been the focus of some relevant agencies 
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(ECDC (European Center for Disease Control and prevention) and EMEA (European Medicines 
Agency) 2009) and some countries have banned the use of antimicrobials as growth promoters 
(Bengtsson & Wierup, 2006). 
 
Resistance today 
The ECDC and EMEA concluded back in 2009 that over 25 000 people die in the EU every year 
from multiresistant bacteria, and that the overall expenses due to multiresistant bacteria for the 
healthcare system are over 1.5 billion euro (ECDC & EMEA, 2009). Multidrug resistance can arise 
in hospitals where antibiotics are frequently used, it is also hypothesized that a high selection for 
antimicrobial resistant genes is occurring where microbes can readily infect new host (ECDC & 
EMEA, 2009). However, other authors point in the direction that the extensive amount of antibiotics 
applied in the farming industry is the main source of multiresistant bacteria (Chee-Sanford et al., 
2009; FDA, 2009; Jensen, 2001).The emergence of these multiresistant bacteria elevates even simple 
surgeries and transplantations to high risk procedures due to increased difficulties combating 
infections (ECDC & EMEA, 2009).   
The recent WHO report on surveillance of antimicrobial resistance, focuses on seven pathogenic 
bacteria of international concern. 
 In hospitals and communities: 
o E. coli resistant to 3rd generation cephalosporins or fluoroquinolones 
o Klebsiella pneumoniae resistant to 3rd generation cephalosporins or 3rd  carbapenems 
o Staphyloccocus aureus resistant to methicillin (MRSA) 
 In communities 
o Streptoccocus pneumoniae resistant or non-susceptible to penicillin 
o Nontyphoidal Salmonella sp. resistant to fluorquinolones 
o Shigella sp. resistant to fluoroquinolones 
o Neisseria gonorrhoeae resistant to cephalosporins 
The K. pneumoniae strain shows resistance to carbapenems which are used as the last resort for 
treatment of infections due to their side effects and  their high price. These antibiotics are used after 
3rd generation cephalosporins, resulting in an extreme increase in economic costs for treatments of 
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three of the seven selected resistant bacteria. Apart from the lethality of these bacteria there is also an 
increased risk of them developing further resistance (WHO, 2014). The consequences of this 
widespread appearance of antibiotic resistance in society and environment are not yet fully 
understood (Martínez & Baquero, 2014). 
Arms race against resistance and emergence of AMPs 
The arms race between the pathogens and antibiotics resulted in attempts to develop of novel 
antimicrobial agents, which has the ability to overcome the action of mechanisms that contribute to 
resistance (Li et al., 2014). The first generation antibiotics defines the naturally occurring and most 
basic existing forms of the antibiotics (Fuoco, 2012; Hester, 2012). Short time after the discovery of 
the first generation antibiotics in 1982, resistant strains occurred resolving in inactivation of the drugs. 
(Davies & Davies, 2010). To keep up with this struggle against resistance the second generation of 
antibiotics came on the market, which were a contribution from research in new fields. The second 
generation was defined by its synthetic modifications and improvements, sometimes also broadening 
their previous spectrum of application (Fuoco, 2012; Hester, 2012). Different antibiotics were 
developed by amplifying the approved first generation antibiotics through modification; hence the 
arms race against resistance commenced (Aminov, 2010). Third generation antibiotics were made 
based on both first and second generations with further improvements sometimes widening the 
spectrum of the antibiotic and sometimes making it highly specific. The development of antibiotics 
has continued yielding both fourth and fifth generations  (Fuoco, 2012; Hester, 2012).  
The amplification of the existing pool of antibiotics from different generations through modification 
rendered the drugs less sensitive towards the mechanisms of antimicrobial resistance. Sooner than 
later pathogens began to develop resistance against the modified antibiotics as well leaving the 
scientist behind in the arms race (Aminov, 2010). 
The arms race against resistance continued with the development of third generation antibiotics in 
response to the earlier mentioned ways that pathogens can acquire resistance towards the used 
compounds. Although the discovered antibiotics have not stopped the resistance mechanisms, they 
significantly slowed them down (Frieden, 2013). The arms race is fragile, and so far the genetic 
evolution seems to be the winner. The antibiotics that have been discovered to counteract the 
resistance mechanisms elaborated on earlier. Inevitably resistance still be developed short after 
against these antibiotics and made them less effective (Dantas & Sommer, 2014). Preventing 
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infections and preventing the spread of resistance could have reduced the emergence of resistance 
mechanisms by some simple precautions: handwashing, safe food preparation, immunization and 
avoiding misuse and overuse of antibiotics (Frieden, 2013). In the next chapter we elaborate on a 
class of antimicrobial agents, the antimicrobial peptides, which have been discovered as potentially 
effective new antibiotics (Aoki & Ueda, 2013).  
Antimicrobial peptides 
Antimicrobial peptides vs. traditional antibiotics 
The mechanisms of killing bacteria of AMPs are different from those of  traditional antibiotics, which 
could make them suitable as potential antimicrobial drugs against multiresistant bacteria (Park et al., 
2011). In addition, AMPs have other properties which make them suitable in the medical industry. 
For example, they are able to remove the soluble debris after bacterial cell death, which can act as 
toxins. Lipopolysaccharides (LPSs) are a structural component of the outer cell membranes of Gram-
negative bacteria, also called a pathogen-associated molecular pattern. When LPSs are found in the 
soluble debris, it provokes the immune system by interaction with the phagocytes (TRL pathway), 
stimulating the production and releasement of cytokines into the circulating blood system. This can 
lead to a septic shock, which can be lethal (Madigan et al., 2009; Srivastava et al., 2013). It is reported 
that after the stimulation of the immune system some AMPs rapidly binds to LPSs with high affinity 
and neutralize the toxicity of LPSs (Ding et al., 2008). In addition, binding with high affinity increases 
the difficulty for a bacteria to develop resistance. This shows that LPS is a fine target for some AMPs, 
which is important in the killing process of the some multidrug-resistant bacteria and preventing 
septic shock (Ding et al., 2008; Li et al., 2004).  
Bacterial biofilm formation increases the antibiotic resistance of bacteria, since the antibiotics are 
unable to translocate into the matrix, thus not reaching the bacteria (Park et al, 2011). However, 
AMPs have an impact on different stages of the formation of a biofilm, where they have potential in 
exhibiting antimicrobial activity towards broad spectrum of microorganisms along with multidrug 
resistant strains (Dawgul et al., 2014). Due to AMPs different mechanisms, it is predicted that AMPs 
have the potential to be anti-biofilm agents (Parker et al., 2011).  
Most of the AMPs are membrane active and disintegrate the bacterial cell wall and the cytoplasmic 
membrane, and this is considered to be an important target (Park et al., 2011; Srivastava et al., 2013). 
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By virtue of this specific mechanism, the bacteria might fail in developing resistance against the 
AMPs due to the conservative nature of the cell membranes which cannot be altered easily. 
(Srivastava et al., 2013, Giuliani et al., 2007). Some of the mechanisms bacteria can employ to resist 
against the effects of AMPs are similar to that towards traditional antibiotics like increased efflux 
pump activity, changing the permeability of the membrane but more sophisticated defences have been 
found (Guilhelmelli et al., 2013). Bacterial modifications that bring a change in charge (more 
positive) of the antimicrobial targets like peptidoglycan or LPS is one way of avoiding being 
recognised by the AMPs. In addition to this both Gram-positive and Gram-negative bacteria can 
secrete proteases and peptidases which will degrade the AMP’s before reaching the bacteria 
(Guilhelmelli et al., 2013; Kraus & Peschel, 2006).  
 
 
Figure 4: Shows a comparison of traditional antibiotics and AMPs in regards to their mode of action on the bacterial cell. 
The arrows indicating the target sites. One major difference is the membrane disruptive effect of some AMPs (Sang & 
Blecha, 2008). 
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Figure 4 shows the different mechanisms of conventional antibiotics and AMPs. The conventional 
antibiotics work by inhibiting the cell wall synthesis. Besides inhibiting the cell wall synthesis, they 
also inhibit DNA, RNA and protein synthesis. The bactericidal mechanisms of AMPs are illustrated 
indicating the propensity to the membrane disruption along with other mechanisms of action such as 
DNA binding and enzyme inhibition (Sang & Blecha, 2008).  
 
Antimicrobial peptides and their modes of action 
AMPs have varying length ranging from five to several hundred amino acid residues, still classifying 
many of them as oligopeptides (Bahar & Ren, 2013). The common range is 12-50 amino acid 
residues, often with a higher ratio of lysine and arginine making these peptides cationic (Hancock, 
1997). AMPs also contain ca. 50% hydrophobic amino acids which gives the peptide an amphipathic 
trait which can be used to interact with hydrophobic membranes (Huang et al., 2010).  
Up to date researchers have identified more than 5.000 AMPs and many of them are under current 
investigation taken (Zhao et al., 2013). For many of these peptides the secondary structure is known 
and they are classed by those: β-structure AMPs,  are forming β-sheet structures as part of their 
secondary structure while α-helix AMPs primarily contain α-helices (Hancock & Lehrer, 1998). β-
structure AMPs are characterized by having at least two β-sheets that are antiparallel and often 
strengthened by disulphide bonds, but can also contain other secondary structures as well (Powers & 
Hancock, 2003). Some AMPs with β-structures have been found to have a high affinity for the 
lipopolysaccharides of Gram-negative cells thereby disrupting their membrane (Hirakura et al., 2002) 
while others like tachyplesin I have shown to interact with the minor groove of DNA (Yonezawa et 
al., 1992). This simple comparison shows the larger difficulties in classifying AMPs by structure 
only. Therefore it was found convenient to class them into modes of membrane interaction, namely 
membrane disruptive and membrane non-disruptive (Powers & Hancock, 2003). 
Membrane disruptive AMPs interact and permeabilize the bilayer in various ways which in the end 
destroys the cell (Huang et al., 2010). Membrane non-disruptive AMPs are not targeting the cell 
membrane but target crucial pathways for cell survival inside the cell much like traditional antibiotics, 
and they are able to differentiate between mammalian and prokaryotic cells. Mammalian membranes 
are rich in zwitterionic phospholipids, giving the membrane charge, and phosphatidylcholine or 
sphingomyelin while the prokaryotic membranes have high amounts of phosphatidylglycerol, 
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cardiolipin or phosphatidylserine (Yeaman & Yount, 2003). In addition many prokaryotic membranes 
are positively charged and are lacking cholesterol found in mammalian cells which has been shown 
to reduce some AMPs activities (Giuliani et al., 2007; Yeaman & Yount, 2003). With these 
differences in membranes, AMPs can selectively target prokaryotic membranes while leaving the 
host cell membranes intact. The membrane disruption mode of action is so far mainly attributed to 
the α-helical AMPs, probably due to the amphipathic properties of some of these helices (Malmsten, 
2014). The same author mentions that a change in the molecular structure of AMPs impeding the 
ability to form α-helices greatly reduces the cytotoxicity of the AMP.     
 
Figure 5: Shows a visual illustration of the primary mode of actions of helical AMPs on membrane activity. The three 
major models of AMP interaction; (A) Barrel-Stave, (B) Carpet-model and (C) Toroidal pore-model are illustrated.  The 
blue colour is the hydrophobic parts of the AMPs whereas the red colour is the hydrophilic parts of the AMPs. (Bahar & 
Ren, 2013)  
Figure 5 by Bahar & Ren (2013) describes the hypotheses for membrane disruption mechanisms by 
α-helical AMPs. When a certain threshold concentration of AMPs is reached, they may integrate into 
the membrane thus making it permeable as seen in A and C. This is happening by the membrane 
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being coated with AMP molecules having the hydrophobic sides facing the membrane and thus leaves 
a pore in the middle (Bahar & Ren, 2013). The Barrel-stave model is basically a peptide lined 
transmembrane pore forming, by vertical insertion into the membrane by amphipathic interactions 
with the membrane (Bahar & Ren, 2013; Nguyen et al., 2011). The Toroidal pore-model is similar to 
the Barrel-Stave model regarding the lipid peptide interaction, although with less molecules thus 
distorting the membrane. The carpet model is where the membrane is degraded by the AMP 
interaction into micellar structures breaking down the bacterial membranes. Other interactions are 
that AMPs can target oxidized lipids or draw out anion carriers by charging the outer leaflet of the 
membrane (Nguyen et al., 2011). Lastly, AMPs can alter the membrane electrochemical potential 
rendering the membrane permeable to various molecules. These models are not mutually exclusive 
and it is very likely that an AMP is using several of the model mechanisms in figure 5 (Nguyen et al., 
2011). 
To ensure AMPs are not targeting host cells many of them need post-translational activation which 
Bahar & Ren (2013) summed up to be happening by the following processes: Phosphorylation, 
addition of D-amino acid, methylation, amidation, glycosylation, formation of disulphide bonds and 
proteolytic cleavage.    
 
The immune system and antimicrobial peptides 
Our body protects itself through innate immunity mechanisms, which has the ability to recognize 
foreign microorganisms (Madigan et al., 2009). After a bacteria has passed the physical and chemical 
barriers of an organism the phagocytes are the next line of defense and are found in fluids and tissues 
(Madigan et al., 2009). When phagocytes get in contact with the pathogens on surfaces, like fibrin 
clots or blood vessel walls, this leads to phagocytosis, the engulfment and internalization of the 
pathogen in the phagocyte as seen in figure 6. This results in the formation of the phagosome. The 
pathogen inside the phagocyte will then be fused together with the lysosome and form the 
phagolysosome. When the phagolysosome is maturing the AMPs get in action and provides 
antimicrobial activity, and therefore eliminate the microbial cell along with the other bactericidal 
substances such as oxygen radicals (Madigan et al., 2009). 
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Figure 6: A bacterium gets in contact with the phagocyte, which destroys it through phagocytosis and the formation of 
phagolysosome. The pathogen is destroyed to soluble debris, which then are excreted from the phagocyte through 
exocytosis (Courtesy of Quizlet, 2015).  
Antimicrobial peptides in the body 
AMPs are naturally occurring molecules which are found in all domains of life. Since resistance is a 
big problem, the demand for antimicrobial agents has become significant. The primary function of 
AMPs is to inhibit the overgrowth of microorganisms (Sidky et al., 2012). The human body contains 
more than 100 AMPs that are already identified from various epithelial surfaces and different tissues 
(Wang, 2014). The untypical AMP, human lysozyme, were discovered by Fleming (1922) in 
secretions such as nasal mucus, but this molecule is also present in different tissues and other 
secretions. There are two major groups of AMPs in mammals and humans, the cathelicidins and 
defensins (Wang, 2014). These two groups of AMPs are most known for their antimicrobial 
properties, they  help against various  problems such as skin diseases, acne, wound, dermatitis etc. 
(Sidky et al., 2012). 
Defensins are cationic molecules. Their structure is stabilized by the three disulfide bonds and based 
on a β-structure core, and they contain 6-8 cysteine residues, and they are able to make disulfide 
bridges (Sidky, et al., 2012). Defensins are especially prominent in humans and are widespread in 
phagocytes and mammalian epithelial cells. They are subdivided by the arrangement of their disulfide 
bridges into α-defensin, β-defensin and θ-defensin shown in figure 7 (Sidky, et al., 2012). 
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Figure 7: Structures of defensins. The α-defensin is a human neutrophil peptide 3 (HNP3). The β-defensin is  human β-
defensin 2 (HBD2) in solution is a monomer. The structure of HBD2 is the same as for α-defensin except of a change in 
the disulphide-bond pattern. The structure of θ-defensin is cyclic and is forming a simple β-sheet (Ganz, 2003). 
Cathelicidins 
Cathelicidins are found in a wide range of species in both plants and animals as part of their innate 
immune system. This shows that it has an old evolutionary history (Kosciuczuk et al., 2012). The 
separate peptide family of cathelicidins was based on the presence of a conservative cathelin domain 
(figure 8) originally discovered in cathelicidins of the insect immune system (Hultmark et al., 1980). 
  
Figure 8: A diagrammatic display of the cathelicidin family structure. The PRE is the precursor part in the N-terminus 
end which is part of the highly conserved cathelin domain as is the PRO. The C-terminus end (PEPTIDE) is very variable 
and is where the antimicrobial structure is found (Zanetti et al., 1995).    
Cathelicidins are polypeptides varying in length with antimicrobial properties stored in neutrophils 
and macrophages from which they are released in an immune response (Kosciuczuk et al., 2012). 
However in humans, there is only one type of cathelicidin, which is known as hCAP-18/LL-37 (Sidky 
et al., 2012). Cathelicidin derived AMPs have been shown to target a broad spectrum of prokaryotes 
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and are effective at low concentrations in the µM range (Zanetti et al., 1995). The proposed mode 
action of these cationic and amphiphilic peptides is a charge interaction between the peptide and the 
negatively charged membrane of some bacteria. This attraction and alignment of peptide and 
membrane neutralizes the charge of the membrane and the amphipathic properties together with the 
secondary structure forms membrane disruptive effects and transmembrane pores (Brogden, 2005; 
Kosciuczuk et al., 2012; Ramanathan et al., 2002). Thus they are effective natural antibacterial 
molecules of the immune system (Ramanathan et al., 2002).   
Structure and function of LL-37  
LL-37 is the only human cathelicidin-related AMP and is one of the best studied AMPs (Malanovic 
et al., 2015). It is called LL-37 because it starts with two leucines and contains 37 amino acids 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) (Gudmundsson et al., 1996; Oren et al., 
1999; Ramanathan et al., 2002).  It is the truncated form of FALL-39 and its precursor is hCAP18, 
but LL-37 is the mature peptide (Oren et al., 1999; Sørensen et al., 2001). The protein is matured 
during and after secretion from secretory granules of neutrophiles (Ramanathan et al., 2002). LL-37 
is α-helical and amphiphilic (Oren et al., 1999; Ramanathan et al., 2002). The structure in SDS 
micelles is illustrated on figure 8 and consists of a helix-bend-helix followed by a disordered tail at 
the C-terminal (Wang, 2008). AMPs containing α-helix motifs have the general function of 
permeabilizing cell membranes of bacteria, and LL-37 is no exception to this, as it is able to rapidly 
permeabilize prone cell membranes of both bacterial and certain eukaryotic cells in the absence of 
human serum (Johansson et al., 1998; Oren et al., 1999). Oren et al., (1999) proposed the carpet 
model for its mechanism of action rather than forming actual pores in the cell membrane. The 
mechanism is illustrated in figure 8. Nell et al. (2006) determined that the C-terminus part (the second 
α-helix) of the molecule displayed the strongest LPS neutralizing activity. 
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Figure 9: LL-37: Backbone structure of several molecules with only the disordered tails not overlapping (A), ribbon 
structure with visible hydrophobic side chains and the helical bend indicated by an arrow (B) and potential surface 
structure with hydrophilic surface beneath (acidic and basic residues in red and blue, respectively)  and hydrophobic 
surface on top (white residues) (C) (Wang, 2008).   
 
Structure and function of OP-145 
The AMP OP-145, earlier known as P60.4Ac, is a derivative of LL-37 and consists primarily of the 
C-terminus part of the naturally occurring peptide leaving OP-145 with the amino acid sequence; 
IGKEFKRIVERIKRFLRELVRPLR. Modifications of the original C-terminal part of this new 
molecule were made to form an amphipathic helix   (Haney & Hancock, 2014; Nell et al., 2006).  OP-
145 was developed from a screening of the human cathelicidin versions (LL-37) by Nell et al. (2006), 
and it displays enhanced antimicrobial activity compared to LL-37 (Malanovic et al., 2015; Nell et 
al., 2006). Nell et al. (2006) found that OP-145 displayed higher antimicrobial activity towards E. 
coli compared to LL-37, with a MIC of 2 µM and 3µM, respectively. The cytotoxic activity of the 
OP-145 towards the Gram-positive S. aureus was assessed by Malanovic et al. (2015), who found 
that more than 50% of the culture was killed at concentrations of 0.8-1.6 µM within 1 hour. OP-145 
also displays lytic activity towards some human cells but at high concentrations (IC50= 32 µM) 
(Malanovic et al., 2015). As OP-145 is a relatively new AMP, the structure is not yet known but it 
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was proved efficient and safe in clinical phase I/II trial for treatment of chronic otitis media (Fjell et 
al., 2012; Malanovic et al., 2015).   
 
Structure and function of lysozyme 
Lysozyme is a 129 residue long single protein chain that forms both α-helices and β- sheets (figure 
9). Its structure was already found in 1965 with dimensions of 45*30*30 Å (Blake et al., 1965). The 
protein has its polar residues on the outside and shields its hydrophobic residues on the inside, making 
the protein hydrophilic (Leśnierowski & Cegielska-Radziejewska, 2012). In the hen egg white 
lysozyme the active site is in a cleft of the enzyme supported by disulphide bonds and its substrate is 
peptidoglycan, which many bacteria have in their membranes, notably Gram-positives. The 
enzymatic effect is carried by hydrolase of the β 1->4 glycosidic bond between N-acetylglucosamine 
and N-acetylmuramic acid (Leśnierowski & Cegielska-Radziejewska, 2012). By breaking the 
peptidoglycan that stabilize and gives the bacterial cell wall structure it will cause the bacteria to lyse 
and rupture (Nelson & Cox, 2013).  
 
Figure 10: A protein-carbohydrate interaction with a mutant Lysozyme from hen egg-white. The carbohydrate ligand 
interacting with the active site of the lysozyme is N-acetyl-D-glucosamine. The β-structure is represented in yellow, the 
pink/purple colour represents α-helical structures, and the bends are represented in blue. Structure: PDB ID 1LZE. 
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Problem formulation 
After considering the theory we have reached the following problem formulation for our 
investigation: 
The structure and mode of action for naturally occurring AMPs are not well characterized. We will 
investigate the structure of a known AMP (lysozyme) and a structurally unidentified AMP (OP-145), 
followed by a comparison of their effectiveness in microbial killing to contribute to a better 
understanding of the relationship between structure and function of these molecules.  
This will be achieved experimentally by crystallization and determination of their structure of 
followed by a growth experiment to determine their effectiveness against Gram-positive and Gram-
negative bacteria, compared to each other and two conventional antimicrobial agents.    
Hypothesis 
We expect that regarding the crystallization and structure determination that the antimicrobial peptide 
OP-145 will be structurally similar to the already crystallized LL-37, which it is derived from. 
Furthermore we expect to be able to discuss its structure compared to its mode of action and when 
compared to the already well-studied lysozyme. 
In the bacterial growth experiments we expect to show that the antimicrobial peptide OP-145 will be 
as effective as LL-37. We expect AMPs to have similar antibiotic effects compared to 
chloramphenicol and we expect the effect of lysozyme to be comparable with the effects of OP-145 
and LL-37. We expect LL-37 and OP-145 to have a synergistic inhibiting effects in the mixed 
treatments with vancomycin on the Gram-negative bacteria as vancomycin should not inhibit these 
alone. The synergistic inhibition effect should not be visible on Gram-positive bacteria as vancomycin 
should be able to inhibit them on its own. The last two expectations are made under the assumption 
that vancomycins mode of action is on the cell wall.  
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Experimental protocol 
Crystallization 
Most modern crystallization methods rely on the principle of vapour diffusion equilibration between 
drop and reservoir. This means that water evaporates out of the protein or peptide samples, making it 
highly saturated and lowering the solubility of the protein in the sample (Scopes, 1994). The water 
ends up in the reservoir which has a higher 
concentration of crystallization reagent than the 
sample drop at the start of the crystallization 
process. In this way, the concentration of reagent 
slowly reaches equilibrium. As the solute 
concentration in the drop rises the proteins in the 
sample become less and less soluble causing 
them to ultimately precipitate in the form of 
crystals. The sitting drop crystallization 
procedure is illustrated in figure 11. This process 
is often aided by precipitation agents, for 
example ammonium sulphate or polyethylene 
glycol. (Scopes, 1994, McPherson, 1976). Normally a wide range of conditions are used to find the 
ideal for crystallization, and the conditions used in this study are found in appendix A.  
In practice a 96-well plate is normally used for crystallization using the sitting drop method. Each 
well has one to three elevations where the drop will be placed. Around the elevated part there is the 
reservoir. Crystallization reagent is pipetted into the reservoir. Next, a small amount of the sample is 
pipetted into the elevated well. The sample consists of the purified protein and usually a buffer 
system. A small amount of precipitant is then added to the samples and mixed with the pipette tip, 
making sure that the sample is dispersed (Walter et al., 2005; Scopes, 1994). The wells are then sealed 
with film or a coverslip and left until crystals develop.   
Crystallization of lysozyme 
Lysozyme solution was prepared by diluting 18.44 mg chicken egg white lysozyme in 250 µL DI-
water achieving a concentration of ~75 mg/mL. Sodium chloride and sodium acetate were used as 
precipitating agents and the precipitating solution was produced by adding 3.26 g NaCl and 0.68 g 
Figure 11: Sitting drop crystallization: Sealed reservoir 
containing precipitation reagent and with single well in 
the middle containing protein solution and precipitation 
reagent. 
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NaOAc to 50 mL deionized-water ending up with 6.5 % NaCl and 0.1 M NaOAc. The pH was 
adjusted to ~4.8 using acetic acid. 
In our approach 80 µL of the precipitating solution was added to the 
reservoir of 8 wells in a flat bottom (Crystalquick sw) 96-well plate. 1 µL 
lysozyme was added to the middle crystallization depression of each 
reservoir followed by the addition of 1 µL precipitant solution taken 
directly from the associated reservoir. The same procedure was done with 
pre-prepared conditions of JCSG kit (producer Qiagen) I with conditions 
listed in Appendix A, which were added to the entire plate. The procedure 
was done by hand as illustrated in figure 11. The plates was then sealed 
off using transparent adhesive film and placed in a styrofoam box for 
crystallization for ca. 2 days.               
Crystallization of OP-145 
The crystallization of our second AMP was conducted similarly to the lysozyme in 96-well plated 
with crystallization wells. In this case three peptide solutions were prepared to ensure that the 
crystallization would be successful: 20 mg/ ml of OP-145 in water, 20 mg/ml OP-145 in water with 
1% LDAO and 20 mg/ml OP-145 in water with 1% DPC. LDAO (N,N-dimethyl-dodecylamine N-
oxide) and DPC (dodecyl phosphocholine) are detergents which have shown promising results with 
crystallization of similar peptides such as OP-145 (Sancho-Vaello et al., unpublished). As before 80 
µL of the precipitating solution was added to the reservoir wells in a flat bottom (Crystalquick sw) 
96 well plate. Four different sets of conditions were used for this purpose as listed in Appendix A 
(JCSG kits I-IV). 0.8 µl of each of the OP-145 solutions were then added to each of the microwells 
so that each reservoir had three different samples. The contents of the microwells were then each 
mixed with 0.8 μl of crystallization solution from the reservoir. As before the samples were covered 
with adhesive film and left in the dark for ca. 2 days. 
Growth experiment method 
An E. coli strain and a B. subtilis strain was used for this experiment, to test the effect of five different 
antibiotics on Gram-negative and Gram-positive bacteria, respectively. The overnight cultures were 
prepared for each species by transferring a single colony to a 50 mL centrifuge tube containing 
approx. 20 mL of LB medium under sterile conditions. The cultures were incubated at 37oC in a 
 
Figure 12: Preparation of a 
crystallization plate. 
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shaking incubator overnight. The overnight cultures were diluted before the experiment and were 
allowed to grow half an hour in the incubator to reach an exponential growth state.  
Stock solutions of each of the different antibiotics were prepared in water. These were further diluted 
in LB in two sterile 96 well microplates to achieve four different concentrations of each of the 
different antibiotics (different for each bacterial species) as illustrated in table 1 and 2. The different 
concentrations were made to achieve a gradient in the effect on the end point of the bacterial growth. 
They were based on a pilot experiment that tested out MICs found in the literature. The different 
concentrations were made in triplicates along with twelve controls containing only LB medium. 
Furthermore triplicates were made of vancomycin in a mixture with LL-37 and OP-145, respectively. 
The compounds in these mixed treatments were in the same concentrations as in the separate 
treatments. The mixed treatments were done to investigate the additive effects of the conventional 
antibiotic and the two AMPs.   
Just before inserting the plates into the microplate reader 10 µL of the exponentially growing cultures 
were added to the wells containing antibiotics and to six of the twelve control wells. The OD595 
measurements were performed at 37 oC for 4 hours with measurements and shaking every 5 minutes 
for E. coli and every 10 minutes for B. subtilis. The parameter read was OD595 which was used as a 
measure of bacterial concentration.  
Table 1: Concentrations of antimicrobials in E. coli treatments 
E. coli 
 LL-37 OP-145 Lysozyme Chloramphenicol Vancomycin 
Concentrations 
[µM] 
13.4 19.7 28 24.8 43.1 
6.7 9.8 14 12.4 21.5 
3.3 4.9 7 6.2 10.8 
1.7 2.5 3.5 3.1 5.4 
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Table 2: Concentrations of antimicrobials in B. subtilis treatments 
B. subtilis 
 LL-37 OP-145 Lysozyme Chloramphenicol Vancomycin 
Concentrations 
[µM] 
13.4 19.7 14 24.8 5.4 
6.7 9.8 7 12.4 2.7 
3.3 4.9 3.5 6.2 1.3 
1.7 2.5 1.8 3.1 0.7 
 
 
Results 
Crystallization 
The crystallization of lysozyme gave large crystals up 
to 500 µm which are usable for X-ray crystallography. 
The crystals are pictured on figure 13. 
The AMP of interest, OP-145, however did not yield 
any crystals despite the multitude of different 
conditions used for the experiment. Some needle and 
crystal-like structures were found, but have turned out 
to originate from the precipitating agents in the 
conditions as they could be found in the reservoir as 
well. The screening tables for these crystallizations can 
be found in Appendix B. Since we did not get the 
desired crystal structure of OP-145, we abandoned the plan to investigate the molecular structures 
experimentally altogether.  
 
 
 
  
 
 
Figure 13: Shows one of the crystals of lysozyme 
obtained through a optical microscope. The green 
line shows the length. From this the crystal seems 
unusually large 
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Bacterial growth experiments 
Figure 14 shows that LL-37 has a substantial inhibiting effect on the growth of E. coli at high 
concentrations. The concentration of LL-37 at 1.7 µM and 3.3 µM does not inhibit the E. coli at all, 
since the curves representing these concentrations are growing parallel with the control and the curve 
is flattening out in a logistic fashion towards the same plateau. The 95% CIs of these curves are 
overlapping with the 95 % CIs of the control suggesting no significant effect of LL-37. However, it 
seems that the more the concentration increases above 3.3 µM, the more LL-37 has an inhibiting 
effect on the growth E. coli - as seen on the graph, the concentrations of LL-37 at 6.7 µM and 13.4 
µM inhibits the growth of E.coli almost completely.  
Figure 14: Growth of E. coli in the presence of LL-37: The growth of E. coli is measured by OD595 over time (sec), 
where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. The 95% confidence intervals 
(CIs) are shown as error bars. 
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Figure 15 shows that chloramphenicol has a negative effect on the growth of E. coli. All of the 
concentrations used inhibited the growth, therefore no minimal inhibitory concentration can be 
defined from the curves, compared to the smooth logistic growth of the control. Although all the 
concentrations inhibit the growth, it seems like the lower concentrations are allowing a very small 
growth  
 
Figure 15: Growth of E. coli in the presence of chloramphenicol: The growth of E. coli is measured by OD595 
over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. 
The 95% CIs are shown as error bars. 
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Figure 16 shows that E. coli is growing even when exposed to higher concentrations of vancomycin, 
and all the curves follow more or less the control in a logistic manner. Vancomycin does not have an 
inhibitory effect at concentrations 5.4 µM and 10.8 µM and 21.5 µM, since the curves representing 
these concentrations have overlapping 95% CIs with the control. However, vancomycin does have 
some inhibitory effect at the highest concentration  (43.1 µM) – the 95% CIs of these curves are not 
overlapping the control. This curve, however, still follows the logistic pattern of growth and the 
bacteria are not inhibited completely. 
 
Figure 16: Growth of E. coli in the presence of vancomycin: The growth of E. coli is measured by OD595 over 
time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. The 
95% CIs are shown as error bars. 
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Figure 17 shows that the E. coli is growing even when exposed to different concentrations of 
lysozyme, since all of the curves are logistically growing. The 95 % CIs are all overlapping the 
control. Therefore, it seems that lysozyme does not inhibit the growth of E. coli, which was expected. 
 
Figure 17: Growth of E. coli in the presence of lysozyme: The growth of E. coli is measured by OD595 over 
time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. Different 
concentrations were used for lysozyme in order to see the effect on E.coli. The 95% CIs are shown as error 
bars. 
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Figure 18 shows that the bacteria, E. coli is growing even when exposed to different concentrations 
of OP-145. These curves show a potential logistic growth pattern and the 95 % CIs are all overlapping 
with the 95 % CIs of the control. From these graphic results, it seems that OP-145 does not inhibit 
the growth of E. coli at any of these concentrations.  
 
 
Figure 18: Growth of E. coli in the presence of OP-145: The growth of E. coli is measured by OD595 over 
time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. The 
95% CIs are shown as error bars. 
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Figure 19 shows an inhibiting effect of LL-37 together with vancomycin at the three higher 
concentrations. However the lowest concentration does not inhibit the growth of E. coli at all. It is 
obvious that the error bars for these curves are overlapping with the control. The highest concentration 
starts out with uninhibited growth following the control but then at 4500 s something happens and 
the growth is almost stops completely. The next lowest concentration seems only to be enough to halt 
the growth for around 8000 s after which the bacteria culture starts growing relative normally.  The 
next highest concentration seems to inhibit the growth completely 
 
Figure 19: Growth of E. coli in the presence of LL-37 and vancomycin: The growth of E. coli is measured by 
OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in 
seconds. The 95% CIs are shown as error bars. 
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Figure 20 shows the growth of E. coli at all concentrations that were used. It is also seen from the 
graph that the CIs overlap with the control, except for the highest concentration. From these data it 
seems that OP-145 together with vancomycin do not inhibit the growth of E. coli at these 
concentrations except for some inhibition at the highest concentration of the two compounds.    
 
Figure 20: Growth of E. coli in the presence of OP-145 and vancomycin: The growth of E. coli is measured 
by OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in 
seconds. The 95% CIs are shown as error bars.  
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From the single vancomycin measurements it can be seen on figure 21 that it does not reduce growth 
much compared to the control. LL-37 on the other hand reduces growth down to medium high 
concentrations but is not effective enough to halt growth of E. coli at medium low concentrations and 
low concentrations. But since both LL-37 and vancomycin cannot inhibit growth alone in the medium 
low concentrations treatment it is striking that the mixed treatment inhibit the growth a lot compared 
to the control. This could suggest that at these concentrations there is a synergistic growth reducing 
effect of the compounds.  
 
Figure 21: The bar chart made from the endpoints (E. coli density at experimental termination) of the LL-37, 
vancomycin and mixed treatment grouped in concentrations. The x-axis shows four categories of the 
concentration levels (high conc., medium high conc., medium low conc. and low conc.) being compared. The 
y-axis is the OD595 measurements.  
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From figure 22, it is seen that the bacteria, B. subtilis has been growing before the start of the OD595 
measurements vary between treatments at the start of the reading. The graphs show that all of the 
curves are logistic growing, which suggests that LL-37 did not inhibit the growth of B. subtilis at 
these concentrations. The curious result is that the control actually has lower growth than the 
treatments although this is not necessarily significant since the CIs of the control overlap with all the 
others. 
 
Figure 22: Growth of B. subtilis in the presence of LL-37: The growth of B. subtilis is measured by OD595 
over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. 
The 95% CIs are shown as error bars. 
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Figure 23 shows that chloramphenicol has an inhibiting effect on the growth of B.subtilis in most 
concentrations. The concentrations above 3.1 µM are especially effective and inhibit the growth of 
E. coli drastically. At the lowest concentrations it is seen that the bacteria are slowly growing until 
they reach the time 6000 sec. After this they start to grow drastically until they seem to level off in a 
logistic shape. None of the 95% CIs overlap the control. 
 
Figure 23: Growth of B. subtilis in the presence of chloramphenicol: The growth of B. subtilis is measured by 
OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in 
seconds. The 95 % CIs are shown as error bars. 
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Figure 24 shows the effect of vancomycin on the bacteria (B. subtilis) with different concentrations. 
These concentrations inhibit the growth of B. subtilis drastically, which is also expected. All the 
concentrations have 95% CIs overlapping with zero which suggests complete inhibition. 
 
Figure 24: Growth of B. subtilis in the presence of vancomycin: The growth of B. subtilis is measured by 
OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in 
seconds. The 95 % CIs are shown as error bars. 
 
 
 
 
 
 
 
 
  
Page 40 of 117 
 
Figure 25 shows that B. subtilis are logistically growing even when different concentrations of 
lysozyme were used. All of the 95% CIs are overlapping with the control suggesting no difference in 
growth between the treatments. It is therefore seen that lysozyme has no inhibiting effect on B. subtilis 
at these concentrations. 
 
Figure 25: Growth of B. subtilis in the presence of lysozyme: The growth of B. subtilis is measured by OD595 
over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. 
The 95 % CIs are shown as error bars. 
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Figure 26 shows that B. subtilis has a logistic growth even in the presence of higher concentrations 
of OP-145. However, for some reason the control actually has a lower endpoint than all of the 
treatments. Besides this, the 95 % CIs of the curves are overlapping with the control. This suggests 
that any effect of OP-145, positive or negative, on B. subtilis is not significant. 
 
Figure 26: Growth of B. subtilis in the presence of OP-145: The growth of B. subtilis is measured by OD595 
over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in seconds. 
The 95 % CIs are shown as error bars. 
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On figure 27 it can be seen that the bacteria has been growing before the OD595 measurement started 
since the OD measurements at the start are varying. LL-37 together with vancomycin seems to have 
an inhibiting effect of the growth of B. subtilis. This effect seems clearer towards the end where the 
error bars for the higher concentrations no longer overlap with the control. The lowest concentration 
seems to be inhibiting growth but after 4000 s the culture returns into a growing phase although with 
a high variance as seen from the large error bars.  
  
Figure 27: Growth of B. subtilis presence of LL-37 and vancomycin: The growth of B. subtilis is measured by 
OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows the time in 
seconds. The 95 % CIs are shown as error bars. 
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Figure 28 shows that OP-145 and vancomycin mixed together have an effect on B. subtilis since most 
of the bacteria from the different treatments do not grow compared to the control. The lowest 
concentration is being inhibited to a point at around 4000 s for then to assume a growth phase. None 
of the treatments have error bars overlapping with the control which suggests they all inhibit the 
growth. 
 
Figure 28: Growth of B. subtilis in the presence of OP-145 and vancomycin: The growth of B. subtilis is 
measured by OD595 over time (sec), where the y-axis shows the OD595 measurement and the x-axis shows 
the time in seconds. The 95 % CIs are shown as error bars. 
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Statistical Analysis 
Table 3 shows the p-values from t-tests ran on end-points from all the treatments and concentrations, 
each compared to the control treatment to established whether or not we can see a significant effect 
of the drug. The data was log transformed in order to make it more normally distributed and reduce 
skewness. Originally the plan was to use an ANOVA for a more precise statistical analysis; however 
the variance between the data sets was not even so t-tests were used instead. 
From the statistical analysis performed on the end points for E. coli we can see a significant effect 
for the two highest concentrations of OP-145 and the three highest concentrations of LL-37 
suggesting that they are effective against this type of pathogen. Chloramphenicol has proven to be 
significantly effective at all concentrations while vancomycin only showed a significant effect at the 
concentration of 21.5 µM. This was a surprising result since vancomycin should not in principle work 
on a Gram-negative bacterium. The lysozyme which is also not active against Gram-negative bacteria 
has not shown any significant effect when compared to the control.  
The combinations of antimicrobial agents showed a significant effect at the two highest 
concentrations of OP-145 and vancomycin, and the three highest concentrations of LL-37 and 
vancomycin. However, nothing can be said about their additive effect until they are compared 
statistically to the single treatments. These tests (not shown in this table) have shown that there is no 
significant additive effect in either of the treatments. 
 
 
 
 
 
 
 
 
 
 
  
Page 45 of 117 
 
Table 3: t-test results for E. coli endpoints 
E. coli treatments tested with a t-test against the control measurements 
LL-37 (13.4 µM) LL-37 (6.7 µM) LL-37 (3.3 µM) LL-37 (1.7 µM) 
P<0.001 P=0.024* P=0.033 P=0.63 
Effect Effect Effect No Effect 
Chloramphenicol (24.8 
µM) 
Chloramphenicol 
(12.4 µM) 
Chloramphenicol (6.2 
µM) 
Chloramphenicol 
(3.1 µM) 
P<0.001 P<0.001 P<0.001 P=0.024* 
Effect Effect Effect Effect 
Vancomycin (43.1 µM) Vancomycin (21.5 
µM) 
Vancomycin (10.8 
µM) 
Vancomycin (5.4 
µM) 
P=0.18 P=0.034 P=0.857* P=0.084 
No Effect Effect No Effect No Effect 
Lysozyme (28 µM) Lysozyme (14 µM) Lysozyme (7 µM) Lysozyme (3.5 µM) 
P=0.191 P=0.167* P=0.661 P=0.211 
No Effect No Effect No Effect No Effect 
OP-145 (19.7 µM) OP-145 (9.8 µM) OP-145 (4.9 µM) OP-145 (2.5 µM) 
P=0.026 P=0.049 P=0.477 P=0.743 
Effect Effect No Effect No Effect 
LL+Vanc (13.4 +43.1 
µM) 
LL+Vanc(6.7+21.5 
µM) 
LL+Vanc(3.3+10.8 
µM) 
LL+Vanc (1.5+2µg) 
P<0.001 P=0.001 P=0.024* P=0.331 
Effect Effect Effect No Effect 
OP-145+Vanc 
(19.7+43.1 µM) 
OP-145+Vanc 
(9.8+21.5 µM) 
OP-145+Vanc 
(4.9+10.8 µM) 
 OP-145+Vanc 
(2.5+5.4 µM) 
P=0.001 P=0.013 P=0.163 P=0.106 
Effect Effect No Effect No Effect 
*Mann-Whitney Rank Sum Test (due to unequal variance) 
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Theis data used for table 4, was as the  E. coli, log transformed in order to get a more normal 
distribution and reduce variance. Here again a t-test was performed between treatment end points and 
control endpoints since the variances were not even between the data sets which ruled out using an 
ANOVA 
From the table 4 we can see that both the OP-145 and LL-37 AMPs had a significant effect at all 
concentrations. It should however be noted that on the growth curves it can be seen that both of the  
treatments have consistently higher growth compared to the control, which is a surprising result. 
Both of the traditional antimicrobial agents, chloramphenicol and vancomycin show a significant 
effect on the bacterium which is not surprising as they should both be active against gram-positive 
bacteria such as B. subtilis. Lysozyme, which should also be active against these types of bacteria, 
showed some strange results: a significant effect at 7 and 1.8 µM and no significant effect at 14 and 
3.5 µM, which is most likely some natural variance in the data. 
The mixed treatments have both shown to be significantly effective at all concentrations. Since there 
seemed to be no real additive effect upon visual inspections, these combinations were not tested 
against the single treatments. 
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Table 4: t-test results for B. subtilis end points 
B.subtilis treatments tested with a t-test against the control measurements 
LL-37 (19.7 µM) LL-37 (9.8 µM) LL-37 (4.9 µM) LL-37 (2.5 µM) 
P<0.001 P<0.001 P=0.005 P=0.006 
Effect Effect Effect Effect 
Chloramphenicol 
(24.8 µM) 
Chloramphenicol 
(12.4 µM) 
Chloramphenicol 
(6.2 µM) 
Chloramphenicol 
(3.1 µM) 
P<0.001 P<0.001 P<0.001 P<0.001 
Effect Effect Effect Effect 
Vancomycin (5.4 µM) Vancomycin (2.7 µM) Vancomycin (1.3 µM) Vancomycin (0.7 µM) 
P<0.001 P<0.001 P<0.001 P<0.001 
Effect Effect Effect Effect 
Lysozyme (14 µM) Lysozyme (7 µM) Lysozyme (3.5 µM) Lysozyme (1.8 µM) 
P=0.101 P=0.002 P=0.548* P=0.013 
No Effect Effect No Effect Effect 
OP-145 (19.7 µM) OP-145 (9.8 µM) OP-145 (4.9 µM) OP-145 (2.5 µM) 
P=0.003 P<0.001 P<0.001 P=0.002 
Effect Effect Effect Effect 
LL+Vanc (13.4+3.4 
µM) 
LL+Vanc (6.7+2.7 
µM) 
LL+Vanc (3.3+1.3 
µM) 
LL+Vanc (1.7+0.7 
µM) 
P=0.024* P<0.001 P<0.001 P=0.024* 
Effect Effect Effect Effect 
OP-145+Vanc 
(19.7+5.4 µM) 
OP-145+Vanc 
(9.8+2.7 µM) 
OP-145+Vanc 
(4.9+1.3 µM) 
OP-145+Vanc 
(2.5+0.7 µM) 
P<0.001 P<0.001 P<0.001 P<0.001 
Effect Effect Effect Effect 
*Mann-Whitney Rank Sum Test (due to unequal variance) 
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Discussion 
Crystallization 
From the results of crystallization it can be seen that only lysozyme gave crystals useful for X-ray 
crystallography. Despite having tried many different conditions and adding the two detergents which 
have worked with the crystallization of LL-37 (Sancho-Vaello et al., Unpublished). The few crystal-
like structures that occurred on our plates have turned out to be salt from the crystallizing conditions. 
This was confirmed by the fact that the crystals were also found in the reservoir besides the wells.  
More conditions and concentrations need to be tried out before the optimal crystallization conditions 
can be identified and this is work which remains to be done in the future. Unfortunately the structure 
of the lysozyme is well known from previous crystallizations so the most interesting result remains 
hidden. The peptide LL-37 was crystallized from concentrations of 20-40 mg/ml by Sancho-Vaello 
et al. (Unpublished paper) compared to 20 mg/ml, so perhaps including a range of higher 
concentrations could have resulted in better crystallizations. The detergent concentration in this 
experiment was also 0.5% as opposed to the 1% used in our own experiment. This may have caused 
issues as for example high concentrations of LDAO can destabilize the protein, causing issues with 
crystallization and higher levels of impurities if the detergent is not of the highest quality (Privé, 
2007).  
A structural difference could also be an influencing factor on the crystallization, but cannot be 
compared entirely as the exact structure of OP-145 is unknown. We can however compare the primary 
structure of the two AMPs, OP-145 and LL-37. Even though the sequences are similar the same 
crystallization conditions may not account for both of them. Parts of the sequences can be seen below 
where the similarities between the two are highlighted in yellow, orange, green and blue.  
OP-145:            IGKEFKRIVERIKRFLRELVRPLR  (Nell et al., 2006) 
LL-37: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (Ramanathan et al., 2002) 
The 3 amino acid motif of LL-37 (red text), where the bend of the helix-bend-helix was located by 
Wang (2008) is placed at the very end of the N-terminal in OP-145 and the first of the two α-helixes 
is thereby absent. This or other structural differences may have prevented OP-145 from crystallizing 
under conditions similar to those successfully crystallizing LL-37. It might be argued that the purity 
of the peptide (in this case 96.55%) may have an effect on crystal formation, however Scopes (1994) 
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argues that this is not an important factor as long as the protein is the only component in the 
supersaturated state.  
Growth experiment 
The threshold concentration of LL-37 observed in figure 14 for E. coli to be between 3.3 and 6.7 µM 
suggests that this is the concentration needed for the peptide to overcome the bacterial defenses and 
lyse them. This is underlined by the statistical analysis in table 3 which shows that these treatments 
are both having a significant effect on the growth. Deduced from the growth curves the optimal 
concentration for halting E. coli growth is in the previous mentioned range. This is lower than what 
Dürr et al. (2006) have found in their review on LL-37 effect on E. coli which was >32 µM but other 
scientist testing the same have found lower ED50 of around 0.3 µM (Chen et al., 2005). The MIC 
was found to be 12.5 µM which over time totally lysed the E. coli cells (Oren et al. 1999). This 
variability is very likely to be due to the conditions in the growth medium since it has experimentally 
been shown that there is a seven-fold variability in LL-37 growth inhibitory effect only due to pH 
changes (Chen et al., 2005). High concentrations of protein are also previously known to precipitate 
in the traditional method for measuring effects of antibiotics on bacterial growth in LB and this could 
have an influence when comparing results (Wu & Hancock, 1999).   
Since LL-37 is a cathelicidin derived AMP it is likely that the concentration is the limit to what E. 
coli cells defense can cope with. One of these recognized defenses of bacteria towards LL-37 is the 
action of a proteinase which cleaves the peptide and leaves it inactivated (Schmidtchen et al., 2002). 
This could be the reason why the lower concentrations cannot inhibit the growth of E. coli. It has 
been shown that LL-37 adhere to the surface of membranes in its helical form (Oren et al., 1999) 
which is in coherence with its amphipathic properties. This adhesion and semi-integration in the 
bacteria membrane disrupt its function as hypothesized by the carpet model (Dürr et al. 2006; Oren 
et al., 1999). It is not yet known exactly what the mode of action on the membrane surface is but the 
effects are clear from Oren et al. (1999), figure 29: 
 
Figure 29: Stained E. coli cells: A, a control cell. C, a cell at 12.5µM LL-37 concentration (Oren et al., 1999). 
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OP-145 is showing little inhibition of growth when comparing the graphs in figure 18. The growth is 
slightly reduced by the AMP but the concentrations are not high enough to suppress bacterial growth. 
Although the difference for the two highest concentrations 6.7 µM and 13.4 µM is significant with 
respect to the normal growth it is far from halting it completely. The reduced growth might be due to 
the fact that bacteria have to allocate more energy to express its defences similar to the proteases that 
cleave LL-37 (Schmidtchen et al., 2002). This type of defence would likely work against this AMP 
as well. Tests have shown that OP-145 also adheres to bacterial model membranes in an α-helical 
structure so its smaller inhibitory effect seems not to be due to failure to recognise its target 
(Malanovic et al., 2015). Perhaps its smaller structure and only one α-helix do not have the same cell 
wall degrading potential but it has been shown that the quasi integration of the peptide induces 
membrane thinning (Malanovic et al., 2015). The same authors claim that at a concentration of 2 µM 
will result in full permeability of artificially created cell membranes mimicking those of Gram-
positive bacteria, which eventually leads to their destruction of the cell. This we did not observe even 
at higher concentrations which may be due to the fact that E. coli is a Gram-negative.       
Chloramphenicol has a strong and significant inhibitory effect on E. coli as indicated in figure 15 and 
Table 3. As stated in the theory, this is due to chloramphenicol targeting the large subunit of the 
bacterial ribosome inhibiting its ability to make peptides (Drainas et al., 1987; Kostopoulou et al., 
2015) This was expected, as this treatment was included as a negative control and has been reported 
to have bactericidal effects even at low concentration by several researchers (Andrews, 2001; White 
et al., 2000). This also shows the effect of traditional antibiotics like chloramphenicol which at a 
concentration around 5 µM completely suppress the growth of E. coli. This is done very effectively 
by another action than membrane targeting explicitly targeting the protein production by obstructing 
ribosomal functions (Kostopoulou et al., 2015). Although very effective as a wide-spectrum antibiotic 
(Kostopoulou et al., 2015) many cases of resistance towards chloramphenicol have been reported like 
the reduction in membrane permeability towards the compound and an increase in efflux pumps 
which are resistance strategies of bacteria also introduced in the introduction chapter (Delcour, 2009; 
Ghisalberti et al., 2005). When turning to our B. subtilis treatment it can be suggested that some of 
these effects are happening in the lowest concentration on figure 23. On the same figure B. subtilis 
growth is initially suppressed by chloramphenicol at all concentrations but after 5000 seconds it 
seems that the bacteria have changed its protein expression increasing its defences to cope with the 
hostile environment in the lowest concentration (Lewis, 2013). This could very well be a case of the 
earlier mentioned increases in efflux pumps in the membranes or reduced permeability of the cell 
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wall to chloramphenicol (Delcour, 2009; Ghisalberti et al., 2005; Nikaido, 2009). As described in the 
theory bacteria (E.coli) can evolve resistance to ciprofloxacin from a small initial population in 
relative short time (10 hours) which could be hypothesised also happened in this treatment (Zhang et 
al., 2011). The alternative to this could be that the concentration simply wasn’t high enough to 
eliminate all the bacteria. The other concentrations seem to be too strong for the bacterias’ defences 
to cope with and no growth is seen which underlines the effectiveness of this traditional antibiotic.     
Vancomycin is our second control which should not target Gram-negative bacteria as E. coli as it is 
normally applied to treat Gram-positive bacteria infections (Yoshida et al., 2011). Vancomycin 
inhibits biosynthesis of peptidoglycans in the bacterial cell wall but since this formation is taking 
place behind the outer cell wall of the Gram-negative bacteria it can not employ its membrane 
disrupting effect (Ibrahim et al., 1992; Yoshida et al., 2011). Therefore it comes as no surprise that 
the treatments of different concentrations follow the normal growth (figure 16). None except the 21.5 
µM concentration treatment differs from the control significantly. It is surprising that at low 
concentration it seems that vancomycin is enhancing the growth of E. coli. This effect has not been 
mentioned in papers so it might just be due to variance in the data. The variance could also be caused 
by handling errors or natural variation in bacteria strains. The slight growth inhibiting effect by the 
AB at high concentrations could be due to its negative effect on cell wall formation but this normally 
only targets Gram-positive bacteria (Yoshida et al., 2011). In regards to B. subtilis, a Gram-positive 
bacteria which does not have the outer membrane, vancomycin works very efficiently as seen on 
figure 24. Even at the lowest concentration vancomycin inhibits the ribosomal activity totally thereby 
preventing B. subtilis from produce peptidoglycan. Over time this results in cell death and we see that 
as no growth in the vancomycin treatments which as we can see from table 4 is also statistically 
significant.    
For lysozyme we observe no significant inhibitory effect on E. coli (Table 3) and also the growth 
curves in the presence of lysozyme mimic the control growth (figure 17). This is expected since 
lysozyme in its natural form cannot interact with the peptidoglycan layer of Gram-negative bacteria 
due to their outer membrane (Ibrahim et al., 1992). This is partly because of lysozymes hydrophilic 
properties. As there is no apparent effect of the slight decrease in growth at higher lysozyme 
concentration this is unlikely to be due to permeability of the outer membrane. Research efforts to 
change lysozyme to have a hydrophobic carrier structure to get past the outer membrane of the cells 
has been done with success (Ibrahim et al., 1992). This shows that changing the structure of some 
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bactericidal compounds can greatly alter their applicability and to circumvent bacterial defences 
against toxic compounds.  
Turning to the Gram-positive bacterium B. subtilis, it seems that the lysozyme concentration was not 
high enough to inhibit its growth very much when looking at figure 25. Due to the large variability 
in the data most of these differences are not significant only the second highest concentration shows 
a clear statistical result (Table 4). It was expected that lysozyme would cleave the peptidoglycan in 
the membrane of the Gram-positive bacteria undermining its stability and ultimately breaking it apart. 
This was not observed but as Ibrahim et al. (1992) points out, lysozyme is not working on all Gram-
positive bacteria and experiments with lysozyme on the cell wall of B. subtilis did not show any lysing 
effect (Thwaites et al, 1991). Apparently B. subtilis is a bacteria which can protect or shield itself 
from the hydrolytic attack on the peptidoglycans by lysozyme. A mechanical twisting of the cell walls 
was observed which could be a protective measure by the bacteria (Thwaites et al., 1991). Another 
possibility could also be that our concentrations were not high enough.   
Combining LL-37 and OP-145 with vancomycin was an effort to see if it would show a synergistic 
effect of the AMPs and vancomycin. These multi antibiotic treatments have shown good results when 
vancomycin was administered in combination with colistin against the multiresistant Acinetobacter 
baumannii (Ceccarelli et al., 2015). Vancomycin alone should not affect the growth of E. coli because 
of the impenetrable outer membrane as mentioned above (Yoshida et al., 2011). Therefore the 
permeabilization of the impermeable outer bacterial membrane by one of the AMPs, should in theory 
increase the effect of vancomycin, enabling vancomycin to pass to the cytoplasmic membrane where 
it prevents the formation of peptidoglycan by action on its precursor (Yoshida et al., 2011). Although 
not statistically significant this cocktail effect is indicated in the mixed treatment with LL-37 and 
vancomycin (3.3 and 10.8 µM respectively) by figure 21. In the higher concentrations LL-37 was 
capable of eliminating the growth of E. coli on its own, but in this treatment neither of the two 
antimicrobials could prevent growth alone (although LL-37 had a significant effect) but in a mixture 
the two compounds have at least a delaying effect on the growth (figure 19). In the rest of the E. coli 
treatments there was no clear case of this. Since as mentioned in the vancomycin discussion the effect 
of vancomycin on Gram-negative bacteria is very limited this comes as no surprise (Yoshida et al., 
2011)       
When investigating the growth of B. subtilis in medium with LL-37 some irregularities become 
apparent. Looking at the figure 22 it can be seen that all concentrations and treatments start at a higher 
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OD595 than the control which might be due to the early addition of the bacteria culture 1 hour in 
advance of the plate reading but with no heating. Although starting at different initial OD595 the lines 
converge to a common line and spread out in the end where we see another unexpected result namely 
that LL-37 actually enhances the growth of B. subtilis. This is unexpected and when comparing the 
endpoints statistically on table 4 all the treatments are significantly higher than the control. Even 
though the endpoints are statistically different the growth curves are not very distinct and at time 
points around 6000 s they are not really distinguishable. That shows that results depend a lot on what 
time point is used to analyze the effect of LL-37, and since we know B. subtilis has a doubling time 
of around 41 min (Wassmann et al., 2011) this growth experiment should have been run for many 
more hours as intended to show a clear result. It is however clear that at these concentration, LL-37 
does not have a bactericidal effect on the Gram-positive bacteria B. subtilis. 
A very similar growth pattern as in the LL-37 treatments is observed in the case of OP-145. Although 
in these treatments the starting concentrations were as expected but as seen on figure 26 the bacteria 
in all treatments exhibit growth to a higher density than the control. Again, this is to our surprise but 
maybe B. subtilis has a way to defend itself against hostile peptides by cleaving them or degrading 
them with proteases which would leave more free amino acids in the medium which could be used 
by the cells for enhanced bacterial growth (Argyle & Baldwin, 1989; Kraus & Peschel, 2006). 
As mentioned above vancomycin inhibits the production of peptidoglycan and for this reason mainly 
inhibits Gram-positive bacteria (Yoshida et al., 2011). The AMPs were therefore only expected to 
have a contributive effect in the mixed treatments if vancomycin itself did not eliminate growth of B. 
subtilis. However all the concentrations of vancomycin chosen were able to prevent bacterial growth. 
Therefore possible additive effects of the peptides together with the chosen vancomycin 
concentrations could not be observed. Rather an antagonistic effect of the two compounds is 
observed, as the lowest concentration in both mixture treatments start to grow at 5000 s. When 
looking at figures 27 and 28 and as discussed both LL-37 and OP-145 somehow enhances the growth 
of B. subtilis. This increase in fitness in the presence of the AMPs could be the reason that the low 
concentration of vancomycin is not enough to inhibit their growth. Another explanation of the sudden 
growth at the mentioned time point could be the same as discussed for chloramphenicol where it is 
argued that the bacteria after some time employs an increased amount of defences rendering 
chloramphenicol useless at low concentrations (Delcour, 2009; Ghisalberti et al., 2005; Nikaido, 
2009). 
  
Page 54 of 117 
 
The increased growth prior to plate reading in B. subtilis for LL-37 both alone and in mixture (figure 
22 and 27.) at lower temperatures is startling since there is a clear relation between concentration of 
LL-37 and bacterial starting OD595. Maybe it is possible for the bacteria to breakdown LL-37 at 
suboptimal temperature using the amino acids from the degraded peptide for growth as free amino 
acids has been shown to greatly enhance bacterial growth (Argyle & Baldwin, 1989). Since LL-37 is 
employed by the human body it could be hypothesized that its temperature optimum is around body 
temperature, leaving it less effective at low (room) temperatures. This does not explain how the 
bacteria in the time of only one hour can manage to grow from an OD595 of 0.0025 to more than 
0.15.    
A recent study by Brown in 2015 describes that the quest for antibiotic compounds maybe should 
focus on the many cofactor compounds that increase the effectiveness of traditional antibiotics by 
lowering the defense capabilities of the bacteria. Many of these compounds are not antimicrobial by 
themselves but can interfere with the immune system of target cell to reduce the MIC of other 
bactericidal compounds. This goes well in conjunction with Chen and colleagues (2005) who state 
that the conditions under which the antibiotics work is important. Therefore, it could be suggested 
that a broad search for synergistic effects outside the antimicrobial compounds could lead to the reuse 
of some of the traditional antibiotics who have lost their effectiveness (Brown, 2015).     
In using a model organism for a Gram-negative (E. coli) and Gram-positive (B. subtilis) we tested 
the effect of two AMPs and compared them to traditional antibiotics. We found that the naturally 
occurring LL-37 and its synthetic derivative OP-145 change the growth significantly compared to the 
control in most concentrations (tables 3 and 4) but for medical applications we expect that zero growth 
is preferred (complete inhibition). As seen from our results, LL-37 at high concentrations can be used 
as an antibiotic against Gram-negative bacteria but not against Gram-positives (figure 14 and 22). 
OP-145 in our concentration range cannot totally inhibit the growth of either E. coli or B. subtilis 
which is surprising since the researchers creating this peptide found that it has a lower MIC of 2 µM 
compared to 3 µM for LL-37 for E. coli (Nell et al., 2006). Efforts to reduce the peptide size but 
retaining or even enhancing its effectiveness were made but this may have lead to loss in target 
recognition or cell membrane interaction (Malanovic et al., 2015; Dürr et al., 2006). The structural 
changes on effective compounds are often done to alter or increase the effectiveness but as we see in 
our experiment that is not always working (Ibrahim et al., 1992). Many similar attempts in 
pharmaceutical biochemistry to create better peptides have been performed and with new methods 
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for creating these the cost of production is also reduced (Larsen, 2011). A point worth mentioning in 
the end is that cathelicidins like LL-37 have been developed at an early point of evolution and bacteria 
could have developed resistance towards them. This has not yet occurred possibly due to LL-37 
targeting the conservative membrane structure of cells (Duplantier & van Hoek, 2013). Keeping this 
in mind it we hope that antibiotics derived from that compound would not generate a fast resistance 
response when applied. 
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Conclusion 
Setting out to find a structure-related effect of OP-145 turned out to be ambitious regarding our time 
constraint and possibilities. Even regarding that we can contribute to the knowledge needed to 
successfully crystallize the peptide in the future. OP-145 does not crystallize under the conditions 
found for LL-37 and more different trials have to be performed before the crystal structure of the 
peptide can be obtained. There is in principle also a chance that a molecule (either protein or peptide) 
does not crystallize at all. The bacterial growth experiment yielded much more promising results. We 
found that LL-37 can suppress the growth of E. coli as a model organism of Gram-negative bacteria 
and that the needed concentration is between 3.3 and 6.7 µM in LB medium but that the parameters 
of appliance can change the concentration range greatly. Even though OP-145 supposedly has a 
similar structure of LL-37 it might not adhere as well to the outer membranes of Gram-negative 
bacteria leaving it an unsuitable AMP against E. coli. The test to see if the traditional antibiotic of 
chloramphenicol halted the growth of E. coli worked at concentrations as low as 5 µM. Followed by 
the other traditional antibiotic vancomycin which did not work on E. coli due to its outer membrane 
which is impermeable to vancomycin. The effect of lysozyme was also impeded by the outer 
membrane since its enzymatic effect could not be employed on peptidoglycans of the inner membrane 
thereby showing no effect as an effective AMP for the used concentration range (3.5-28 µM) for 
Gram-negative bacteria. The effort to show a synergistic effect between vancomycin and the two 
AMPs did not yield promising results from our set up but the potential for cocktail effects even with 
none bactericidal compounds are an important research topic.     
LL-37 and OP-145, do not seem to have any negative effect on the endpoints of the approx. 4 hours 
of growth of B. subtilis and neither of the three investigated peptides were able to eliminate the growth 
at the chosen concentrations. The treatments containing LL-37 and OP-145 had significantly higher 
endpoints compared to the control and both peptides appear to have a weak positive effect on the 
growth. This increased growth is also seen in the prior to OD595 measurements in B. subtilis in LL-
37 containing treatments, possibly due to degradation and use of the amino acids at for the peptide 
suboptimal temperature. There were no clear patterns from the effect of lysozyme on B. subtilis. The 
results of the two conventional antibiotics were as expected. Both chloramphenicol and vancomycin 
were able to eliminate the growth of B. subtilis at high concentrations, but the lowest concentration 
of chloramphenicol (3.1 µM) was only stalling the growth, which is in coherence with other authors. 
As vancomycin eliminated the growth of the Gram-positive bacterium there were no visible results 
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of the experiment regarding a possible cocktail effect of treatment with vancomycin in a mixture with 
LL-37 and OP-145, respectively.  
Although efforts are made to structurally modify peptides for enhanced applicability as antibiotics it 
does not seem clear from our experiment if these compounds are as effective as their natural 
precursors. Possible synergistic effects of drugs also hold promises for the use in the pharmaceutical 
industry and maybe the search for components for the cocktail effect have to be sought outside the 
antibacterial field.  
This investigation shows that the search for novel antibiotic treatments is an interdisciplinary field 
considering structural biology, biochemistry and medical biology, which together try to paint an 
understandable but complex picture of the effects of antibiotic compounds in an ever changing 
environment.   
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Appendixes 
Appendix A 
JCSG Crystallization kits used in the crystallization experiment. Each Core Suit corresponds to one 96-well plate.  
 
The JCSG Core Suite I Composition Table 
Solution 
Plate 
number, 
well 
(24-well 
plates) 
Well (96 
well-
plates) Salt 1 Salt 2 Buffer  Precipitant 1 Precipitant 2 Precipitant 3 
Final 
pH 
Cat. No. 
(Refill-
Hit 
Solution
; 
4 x 12.5 
ml 
tubes) 
1 1,A1 A01   
0.1 M CHES pH 
9.5 
20 %(w/v) PEG 
8000    136201 
2 1,A2 A02   
0.1 M Bicine pH 
8.5 
20 %(w/v) PEG 
6000   9.0 136202 
3 1,A3 A03 
0.05 M Lithium 
sulfate 
0.05 M Sodium 
sulfate 
0.05 M Tris-HCl 
pH 8.5 
30 %(w/v) PEG 
400    136203 
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4 1,A4 A04 
0.2 M Ammonium 
dihydrogen phosphate  0.1 M Tris pH 8.5 50 %(v/v) MPD    136204 
5 1,A5 A05 
0.2 M Magnesium 
chloride  0.1 M Tris pH 8.5 
3.4 M 1,6 
Hexanediol    136205 
6 1,A6 A06 
0.05 M Magnesium 
chloride  0.1M Tris pH 8.5 
40%(v/v) 
Ethanol    136206 
7 1,B1 A07   
0.2 M tri-
Potassium citrate  
20%(w/v) PEG 
3350    136207 
8 1,B2 A08   
0.2 M tri-Sodium 
citrate  
20%(w/v) PEG 
3350    136208 
9 1,B3 A09   
0.2 M tri-Lithium 
citrate  
20%(w/v) PEG 
3350    136209 
10 1,B4 A10 
0.2 M Calcium 
acetate  
0.1 M Imidazole 
pH 8.0 20 %PEG 1000    136210 
11 1,B5 A11   
0.2 M Potassium 
acetate 
20%(w/v) PEG 
3350    136211 
12 1,B6 A12   
0.2 M 
Magnesium 
acetate  
20%(w/v) PEG 
3350    136212 
13 1,C1 B01 
0.2 M Sodium 
chloride  
0.1 M HEPES pH 
7.5 
20 %(w/v) PEG 
3000    136213 
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14 1,C2 B02   
0.1 M HEPES pH 
7.5 
20 %(w/v) PEG 
8000    136214 
15 1,C3 B03   
0.1 M HEPES pH 
7.5 
10 %(w/v) PEG 
8000    136215 
16 1,C4 B04 
0.19 M Calcium 
chloride  
0.095 M HEPES 
pH 7.5 
26.6%(v/v) PEG 
400 
5 %(v/v) 
Glycerol   136216 
17 1,C5 B05   
0.1 M HEPES pH 
7.5 
20 %(w/v) PEG 
4000 
10 %(v/v) 
Isopropanol   136217 
18 1,C6 B06 
0.8 M di-Sodium 
hydrogen phosphate 
0.8 M di-Potassium 
hydrogen phosphate 
0.1 M HEPES pH 
7.5     136218 
19 1,D1 B07 
0.2 M di-Sodium 
tartrate    
20%(w/v) PEG 
3350    136219 
20 1,D2 B08 
0.2 M Calcium 
acetate hydrate   
20%(w/v) PEG 
3350    136220 
21 1,D3 B09 
0.2 M Potassium 
formate   
20%(w/v) PEG 
3350    136221 
22 1,D4 B10 
0.2 M Potassium 
Sodium tartrate    
20%(w/v) PEG 
3350    136222 
23 1,D5 B11 
0.2 M Sodium 
formate   
20%(w/v) PEG 
3350    136223 
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24 1,D6 B12 
0.2 M Potassium 
fluoride   
20%(w/v) PEG 
3350    136224 
25 2,A1 C01 
0.2 M Ammonium 
acetate   
20%(w/v) PEG 
3350    136225 
26 2,A2 C02 0.2 M Lithium nitrate   
20%(w/v) PEG 
3350    136226 
27 2,A3 C03   
0.1M Sodium 
cacodylate pH 6.5 
5%(w/v) PEG 
8000 40%(v/v) MPD   136227 
28 2,A4 C04 
0.2 M Magnesium 
chloride  0.1 M Tris pH 7.0 
10 %(w/v) PEG 
8000    136228 
29 2,A5 C05 
0.2 M Calcium 
acetate  0.1 M Tris pH 7.0 
20 %(w/v) PEG 
3000    136229 
30 2,A6 C06 
0.2 M Magnesium 
chloride  0.1 M Tris pH 7.0 
2.5 M Sodium 
chloride    136230 
31 2,B1 C07   0.1 M Tris pH 7.0 
20 %(w/v) PEG 
2000 MME    136231 
32 2,B2 C08 0.2 M Sodium acetate    
20%(w/v) PEG 
3350    136232 
33 2,B3 C09 
0.2 M Potassium 
thiocyanate   
20%(w/v) PEG 
3350    136233 
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34 2,B4 C10   
0.1 M HEPES pH 
6.5 
20 %(w/v) PEG 
6000   7.0 136234 
35 2,B5 C11 
0.2 M Potassium 
nitrate   
20%(w/v) PEG 
3350    136235 
36 2,B6 C12 
0.2 M Sodium 
thiocyanate   
20%(w/v) PEG 
3350    136236 
37 2,C1 D01 0.2 M Sodium iodide   
20%(w/v) PEG 
3350    136237 
38 2,C2 D02 
0.2 M Potassium 
chloride   
20%(w/v) PEG 
3350    136238 
39 2,C3 D03 
0.2 M Sodium 
chloride   
20%(w/v) PEG 
3350    136239 
40 2,C4 D04 
0.2 M Potassium 
iodide   
20%(w/v) PEG 
3350    136240 
41 2,C5 D05 
0.2 M Lithium 
chloride    
20%(w/v) PEG 
3350    136241 
42 2,C6 D06 
0.2 M Magnesium 
chloride  
0.1M Sodium 
cacodylate pH 6.5  
50%(v/v) PEG 
200    136242 
43 2,D1 D07 
0.2 M di-Ammonium 
tartrate   
20%(w/v) PEG 
3350    136243 
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44 2,D2 D08 0.2 M Sodium sulfate    
20%(w/v) PEG 
3350    136244 
45 2,D3 D09 
0.2 M Ammonium 
formate   
20%(w/v) PEG 
3350    136245 
46 2,D4 D10   
0.1 M HEPES pH 
7.5  
10 %(w/v) PEG 
6000 5 %(v/v) MPD   136246 
47 2,D5 D11   
1.6 M Sodium 
citrate pH 6.5     136247 
48 2,D6 D12 
0.2 M Magnesium 
acetate  
0.1 M Sodium 
cacodylate pH 6.5 
20 %(w/v) PEG 
8000    136248 
49 3,A1 E01 
0.2 M Ammonium 
nitrate   
20%(w/v) PEG 
3350    136249 
50 3,A2 E02 
0.2 M Ammonium 
chloride   
20%(w/v) PEG 
3350    136250 
51 3,A3 E03 
0.2 M Sodium 
chloride  
0.1 M Na/K 
phosphate pH 6.2 
10 %(w/v) PEG 
8000    136251 
52 3,A4 E04 
0.2 M Ammonium 
iodide   
20%(w/v) PEG 
3350    136252 
53 3,A5 E05 
0.2 M Ammonium 
fluoride   
20%(w/v) PEG 
3350    136253 
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54 3,A6 E06   
0.1M MES pH 
6.0 
5%(w/v) PEG 
3000 
30%(v/v) PEG 
200   136254 
55 3,B1 E07 
0.2 M Calcium 
acetate  
0.1 M MES pH 
6.0 
20 %(w/v) PEG 
8000    136255 
56 3,B2 E08 0.2 M Lithium sulfate  
0.1 M MES pH 
6.0 35 %(v/v) MPD    136256 
57 3,B3 E09 
0.2 M Ammonium 
sulfate   
20%(w/v) PEG 
3350    136257 
58 3,B4 E10   
0.1 M MES pH 
5.0 40 %(v/v) MPD   6.0 136258 
59 3,B5 E11   
0.1 M MES pH 
5.0 20 %(v/v) MPD   6.0 136259 
60 3,B6 E12   
0.1 M MES pH 
5.0 
20 %(w/v) PEG 
6000   6.0 136260 
61 3,C1 F01   
0.1 M MES pH 
5.0 
10 %(w/v) PEG 
6000   6.0 136261 
62 3,C2 F02 
0.2 M Magnesium 
sulfate    
20%(w/v) PEG 
3350    136262 
63 3,C3 F03 
0.2 M Magnesium 
formate   
20%(w/v) PEG 
3350    136263 
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64 3,C4 F04 
0.2 M Magnesium 
nitrate    
20%(w/v) PEG 
3350    136264 
65 3,C5 F05 
0.2 M Magnesium 
chloride    
20%(w/v) PEG 
3350    136265 
66 3,C6 F06   
0.095 M Sodium 
citrate pH 5.6 
19 %(v/v) 
Isopropanol 
19 %(w/v) 
PEG 4000 
5 %(v/v) 
Glycerol  136266 
67 3,D1 F07   
0.1 M Sodium 
citrate pH 5.6 
20 %(v/v) 
Isopropanol 
20 %(w/v) 
PEG 4000   136267 
68 3,D2 F08   
0.1 M Sodium 
citrate pH 5.5 
20 %(w/v) PEG 
3000    136268 
69 3,D3 F09 
0.2 M Sodium 
chloride  
0.1M Phosphate-
citrate pH 4.2 
50%(v/v) PEG 
200    136269 
70 3,D4 F10   
0.1M Phosphate-
citrate pH 4.2 
5%(w/v) PEG 
1000 40% Ethanol   136270 
71 3,D5 F11 0.2 M Lithium sulfate  
0.1M Sodium 
acetate pH 4.5 
50%(v/v) PEG 
400    136271 
72 3,D6 F12   
0.1M Phosphate-
citrate pH 4.2 40%(v/v) MPD    136272 
73 4,A1 G01   
0.18 M tri-
Ammonium 
citrate 
20%(w/v) PEG 
3350    136273 
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74 4,A2 G02   
0.1 M Sodium 
acetate pH 5.0 20 %(v/v) MPD    136274 
75 4,A3 G03 
1.0 M Lithium 
chloride  
0.1 M Citric Acid 
pH 5.0 
10 %(w/v) PEG 
6000   5.0 136275 
76 4,A4 G04   
0.1 M Citric Acid 
pH 4.0 
20 %(w/v) PEG 
6000   5.0 136276 
77 4,A5 G05   0.1 M Citric Acid 
10 %(w/v) PEG 
6000   5.0 136277 
78 4,A6 G06   
0.1 M Citric Acid 
pH 4.0 
5 %(w/v) PEG 
6000   5.0 136278 
79 4,B1 G07 
0.2 M Potassium 
dihydrogen phosphate   
20%(w/v) PEG 
3350    136279 
80 4,B2 G08 
0.2 M Ammonium 
dihydrogen phosphate   
20%(w/v) PEG 
3350    136280 
81 4,B3 G09 
0.2 M Ammonium 
sulfate  
0.1 M Sodium 
acetate pH 4.6 
30 %(w/v) PEG 
2000 MME    136281 
82 4,B4 G10   
0.1 M Sodium 
acetate pH 4.6 
8 %(w/v) PEG 
4000    136282 
83 4,B5 G11 
0.2 M Ammonium 
sulfate  
0.1 M Sodium 
acetate pH 4.6 
25 %(w/v) PEG 
4000    136283 
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84 4,B6 G12 
0.02 M Calcium 
chloride  
0.1 M Sodium 
acetate pH 4.6 30 %(v/v) MPD    136284 
85 4,C1 H01   
0.1 M Sodium 
acetate pH 4.5 35 %(v/v) MPD    136285 
86 4,C2 H02   
0.1 M Sodium 
acetate pH 4.5 
20 %(w/v) PEG 
3000    136286 
87 4,C3 H03 
0.2 M Sodium 
dihydrogen phosphate    
20%(w/v) PEG 
3350    136287 
88 4,C4 H04 
0.05 M Potassium 
dihydrogen phosphate   
20 %(w/v) PEG 
8000    136288 
89 4,C5 H05 
0.2 M Sodium 
chloride  
0.1 M Phosphate-
citrate pH 4.2 
10 %(w/v) PEG 
3000    136289 
90 4,C6 H06   
0.1 M 
Phosphate/citrate 
pH 4.2 
2.0 M 
Ammonium 
sulfate    136290 
91 4,D1 H07 0.2 M Lithium sulfate  
0.1 M Phosphate-
citrate pH 4.2 
20 %(w/v) PEG 
1000    136291 
92 4,D2 H08   
0.1 M Citric Acid 
pH 2.5 20 %(v/v) MPD   4.0 136292 
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93 4,D3 H09   
0.1 M Citric Acid 
pH 3.5 
0.8 M 
Ammonium 
sulfate   4.0 136293 
94 4,D4 H10 
1.0 M Lithium 
chloride  
0.1 M Citric Acid 
pH 4.0 
20 %(w/v) PEG 
6000   4.0 136294 
95 4,D5 H11 
1.0 M Lithium 
chloride  
0.1 M Citric Acid 
pH 4.0 
10 %(w/v) PEG 
6000   4.0 136295 
96 4,D6 H12   
0.1 M Citric Acid 
pH 4.0 
5 %(w/v) PEG 
6000   4.0 136296 
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The JCSG Core Suite II Composition Table 
Solution 
Plate 
number, 
well 
(24-well 
plates) 
Well 
(96-well 
plates) Salt Buffer Precipitant 1 Precipitant 2 Precipitant 3 
final 
pH 
Cat. No. 
(Refill-
Hit 
Solution, 
4 x 12.5 
ml tubes) 
1 1,A1 A01 0.2 M Sodium chloride 
0.1 M CAPS pH 
10.5 20%(w/v) PEG 8000    136301 
2 1,A2 A02 0.2 M Sodium chloride 
0.1 M CHES pH 
9.5 
1.26 M Ammonium 
sulfate    136302 
3 1,A3 A03 1.0 M Sodium citrate 
0.1 M CHES pH 
9.5     136303 
4 1,A4 A04 0.2 M Sodium chloride 
0.1 M CHES pH 
9.5 10%(w/v) PEG 8000    136304 
5 1,A5 A05  
0.1 M Bicine pH 
9.0 
10%(w/v) PEG 
20000 2%(v/v) 1,4-Dioxane   136305 
6 1,A6 A06 0.1 M Sodium chloride 
0.1 M Bicine pH 
9.0 
20%(w/v) PEG 550 
MME    136306 
7 1,B1 A07 1.0 M Lithium chloride 
0.1 M Bicine pH 
9.0 10%(w/v) PEG 6000   9.0 136307 
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8 1,B2 A08  0.1M Tris pH 8.5 5%(w/v) PEG 8000 20%(v/v) PEG 300 
10%(v/v) 
Glycerol  136308 
9 1,B3 A09 0.01 M Nickel chloride 
0.1 M Tris pH 
8.5 
20%(w/v) PEG 2000 
MME    136309 
10 1,B4 A10  
0.1 M Tris pH 
8.5 20%(v/v) Ethanol    136310 
11 1,B5 A11  
0.1 M Tris-HCl 
pH 8.5 
2.0 M Ammonium 
dihydrogen 
phosphate    136311 
12 1,B6 A12  
0.1 M Tris-HCl 
pH 8.5 8%(w/v) PEG 8000    136312 
13 1,C1 B01  
0.1 M Tris-HCl 
pH 8.5 
2.0 M Ammonium 
sulfate    136313 
14 1,C2 B02 0.2 M Lithium sulfate 0.1M Tris pH 8.5 40%(v/v) PEG 400    136314 
15 1,C3 B03 0.2 M Calcium acetate 
0.1 M Imidazole 
pH 8.0 10%(w/v) PEG 8000    136315 
16 1,C4 B04 0.2 M Magnesium chloride 
0.1 M Imidazole 
pH 8.0 35%(v/v) MPD    136316 
17 1,C5 B05 1.0 M Lithium chloride 
0.1 M Tris pH 
8.5 20%(w/v) PEG 6000   8.0 136317 
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18 1,C6 B06  
0.1 M Tris pH 
8.5 20%(w/v) PEG 6000   8.0 136318 
19 1,D1 B07 0.2 M Lithium Acetate  20%(w/v) PEG 3350    136319 
20 1,D2 B08 0.2 M Magnesium chloride 
0.1M Imidazole 
pH 8.0 40%(v/v) MPD    136320 
21 1,D3 B09 0.2 M Magnesium chloride 
0.1 M HEPES 
pH 7.5 15%(v/v) Ethanol    136321 
22 1,D4 B10  
0.1 M HEPES 
pH 7.5 70%(v/v) MPD    136322 
23 1,D5 B11  
0.085 M Sodium 
HEPES pH 7.5 17%(w/v) PEG 4000 15%(v/v) Glycerol 
8.5%(v/v) 
Isopropanol  136323 
24 1,D6 B12 
0.6 M sodium dihydrogen 
phosphate/0.6 M potassium 
dihydrogen phosphate 
0.075 M Sodium 
HEPES pH 7.5 25%(v/v) Glycerol    136324 
25 2,A1 C01 0.18 M Magnesium chloride 
0.09 M Sodium 
HEPES pH 7.5 27%(v/v) PEG 400 10%(v/v) Glycerol   136325 
26 2,A2 C02  
0.1 M Sodium 
HEPES pH 7.5 2%(v/v) PEG 400 
2.0 M Ammonium 
sulfate   136326 
27 2,A3 C03 0.2 M Magnesium chloride 
0.1 M Sodium 
HEPES pH 7.5 30%(v/v) PEG 400    136327 
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28 2,A4 C04 0.2 M Sodium chloride 
0.1M Na/K 
phosphate pH 6.2 50%(v/v) PEG 200    136328 
29 2,A5 C05 0.2 M Sodium fluoride  20%(w/v) PEG 3350    136329 
30 2,A6 C06 0.2 M Lithium sulfate 
0.1 M Tris pH 
7.0 
2.0 M Ammonium 
sulfate    136330 
31 2,B1 C07 0.2 M Calcium acetate 
0.1M Sodium 
cacodylate pH 
6.5 40%(v/v) PEG 300    136331 
32 2,B2 C08  
0.1 M Tris pH 
7.0 20%(w/v) PEG 1000    136332 
33 2,B3 C09 1.0 M Lithium chloride 
0.1 M HEPES 
pH 7.0 10%(w/v) PEG 6000   7.0 136333 
34 2,B4 C10  
0.1 M HEPES 
pH 6.5 10%(w/v) PEG 6000   7.0 136334 
35 2,B5 C11 0.2 M Sodium chloride 
0.1M Na/K 
phosphate pH 6.2 40%(v/v) PEG 400    136335 
36 2,B6 C12  
0.1M Sodium 
citrate pH 5.5 50%(v/v) PEG 200    136336 
37 2,C1 D01  
0.1M Na/K 
phosphate pH 6.2 
25%(v/v) 1,2-
Propanediol 10%(v/v) Glycerol   136337 
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38 2,C2 D02 0.2 M Sodium nitrate  20%(w/v) PEG 3350    136338 
39 2,C3 D03 0.05 M Lithium sulfate 0.1M Tris pH 7.0 50%(v/v) PEG 200    136339 
40 2,C4 D04 0.2 M Potassium sulfate  20%(w/v) PEG 3350    136340 
41 2,C5 D05 0.2 M Magnesium formate      136341 
42 2,C6 D06  
0.1MSodium 
citrate pH 5.5 40%(v/v) PEG 600    136342 
43 2,D1 D07 0.2 M Magnesium chloride 
0.1 M Sodium 
cacodylate pH 
6.5 20%(w/v) PEG 1000    136343 
44 2,D2 D08 0.2 M Magnesium chloride 
0.1 M Sodium 
cacodylate pH 
6.5 10%(w/v) PEG 3000    136344 
45 2,D3 D09 0.2 M Lithium sulfate 
0.1 M Sodium 
cacodylate pH 
6.5 30%(v/v) PEG 400    136345 
46 2,D4 D10 0.2 M Sodium chloride 
0.1 M Sodium 
cacodylate pH 
6.5 
2.0 M Ammonium 
sulfate    136346 
47 2,D5 D11  
0.1 M MES pH 
6.5 
12%(w/v) PEG 
20000    136347 
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48 2,D6 D12 0.2 M Lithium sulfate  20%(w/v) PEG 3350    136348 
49 3,A1 E01 0.2 M Sodium chloride 
0.1 M Na/K 
phosphate pH 6.2 20%(w/v) PEG 1000    136349 
50 3,A2 E02  
0.1 M MES pH 
5.0 10%(v/v) MPD   6.0 136350 
51 3,A3 E03 1.0 M Lithium chloride 
0.1 M MES pH 
6.0 20%(w/v) PEG 6000   6.0 136351 
52 3,A4 E04 1.0 M Lithium chloride 
0.1 M MES pH 
6.0 10%(w/v) PEG 6000   6.0 136352 
53 3,A5 E05  
0.1 M MES pH 
5.0 5%(w/v) PEG 6000   6.0 136353 
54 3,A6 E06 0.2 M Zinc acetate 
0.1M Imidazole 
pH 8.0 
25%(v/v) 1,2-
Propanediol 10%(v/v) Glycerol   136354 
55 3,B1 E07 0.2 M Zinc acetate 
0.1M Imidazole 
pH 8.0 40%(v/v) PEG 600    136355 
56 3,B2 E08 0.5 M Ammonium sulfate 0.1M Tris pH 7.0 30%(v/v) PEG 600 10%(v/v) Glycerol   136356 
57 3,B3 E09 1.0 M Lithium sulfate 
0.1 M Sodium 
citrate pH 5.6 
0.5 M Ammonium 
sulfate    136357 
58 3,B4 E10 0.2 M Ammonium acetate 
0.1 M Sodium 
citrate pH 5.6 30%(w/v) PEG 4000    136358 
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59 3,B5 E11   24%(w/v) PEG 1500 20%(v/v) Glycerol   136359 
60 3,B6 E12 0.2 M Sodium chloride 
0.1M Sodium 
acetate pH 4.5 40%(v/v) PEG 300    136360 
61 3,C1 F01  
0.1M Sodium 
acetate pH 4.5 35%(v/v) MPD 10%(v/v) Glycerol   136361 
62 3,C2 F02  
0.1M Phosphate-
citrate pH 4.2 40%(v/v) PEG 300    136362 
63 3,C3 F03  
0.1M Sodium 
acetate pH 4.5 5%(w/v) PEG 1000 
50%(v/v) Ethylene 
glycol   136363 
64 3,C4 F04 0.1 M Sodium chloride 
0.1M Sodium 
acetate pH 4.5 30%(v/v) PEG 200    136364 
65 3,C5 F05  
0.1M Sodium 
acetate pH 4.5 
40%(v/v) 1,2-
Propanediol    136365 
66 3,C6 F06  
0.1M Sodium 
acetate pH 4.5 
40%(v/v) Ethylene 
glycol    136366 
67 3,D1 F07  
0.1 M Sodium 
acetate pH 5.0 10%(v/v) MPD   5.0 136367 
68 3,D2 F08  
0.1 M Citric acid 
pH 4.0 
2.4 M Ammonium 
sulfate   5.0 136368 
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69 3,D3 F09  
0.1 M Citric acid 
pH 4.0 
1.6 M Ammonium 
sulfate   5.0 136369 
70 3,D4 F10  
0.1 M Citric acid 
pH 4.0 
0.8 M Ammonium 
sulfate   5.0 136370 
71 3,D5 F11 1.0 M Lithium chloride 
0.1 M Citric acid 
pH 5.0 20%(w/v) PEG 6000   5.0 136371 
72 3,D6 F12  
0.1M Phosphate-
citrate pH 4.2 5%(w/v) PEG 3000 
25%(v/v) 1,2-
Propanediol 
10%(v/v) 
Glycerol  136372 
73 4,A1 G01   
2.0 M Ammonium 
sulfate 5%(v/v) Isopropanol.   136373 
74 4,A2 G02   
2.0 M Ammonium 
sulfate    136374 
75 4,A3 G03 0.2 M Magnesium chloride 
0.1M MES pH 
5.5 40%(v/v) PEG 400    136375 
76 4,A4 G04 0.01 M Cobalt chloride 
0.1 M Sodium 
acetate pH 4.6 1.0 M Hexanediol    136376 
77 4,A5 G05  
0.08 M Sodium 
acetate pH 4.6 
1.6 M Ammonium 
sulfate 20%(v/v) Glycerol   136377 
78 4,A6 G06  
0.07 M Sodium 
acetate pH 4.6 5.6%(w/v) PEG 4000 30%(v/v) Glycerol   136378 
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79 4,B1 G07 0.14 M Calcium chloride 
0.07 M Sodium 
acetate pH 4.6 30%(v/v) Glycerol 14%(v/v) Isopropanol   136379 
80 4,B2 G08 0.16 M Ammonium sulfate 
0.08 M Sodium 
acetate pH 4.6 20%(w/v) PEG 4000 20%(v/v) Glycerol   136380 
81 4,B3 G09 0.018 M Calcium chloride 
0.09 M Sodium 
acetate pH 4.6 27%(v/v) MPD 10%(v/v) Glycerol   136381 
82 4,B4 G10  
0.1 M Sodium 
acetate pH 4.6 
2.0 M Ammonium 
sulfate    136382 
83 4,B5 G11 0.2 M Zinc acetate 
0.1 M Sodium 
acetate pH 4.5 10%(w/v) PEG 3000    136383 
84 4,B6 G12 0.2 M Ammonium sulfate 
0.1M Phosphate-
citrate pH 4.2 20%(v/v) PEG 300 10% Glycerol   136384 
85 4,C1 H01 0.2 M Calcium acetate 
0.1 M Sodium 
acetate pH 4.5 30%(v/v) PEG 400    136385 
86 4,C2 H02 0.2 M Lithium sulfate 
0.1 M Sodium 
acetate pH 4.5 30%(w/v) PEG 8000    136386 
87 4,C3 H03   
25%(v/v) Ethylene 
glycol    136387 
88 4,C4 H04 0.2 M Lithium sulfate 
0.1 M Phosphate-
citrate pH 4.2 
10%(v/v) 
Isopropanol    136388 
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89 4,C5 H05 0.2 M Sodium chloride 
0.1 M Phosphate-
citrate pH 4.2 20%(w/v) PEG 8000    136389 
90 4,C6 H06   10%(w/v) PEG 1000 10%(w/v) PEG 8000   136390 
91 4,D1 H07 0.17 M Ammonium sulfate  
25.5%(w/v) PEG 
4000 15%(v/v) Glycerol   136391 
92 4,D2 H08   30%(w/v) PEG 1500    136392 
93 4,D3 H09 
0.4 M Ammonium dihydrogen 
phosphate      136393 
94 4,D4 H10   
35%(v/v) 1,4-
Dioxane    136394 
95 4,D5 H11  
0.1 M Citric acid 
pH 2.5 10%(v/v) MPD   4.0 136395 
96 4,D6 H12  
0.1 M Citric acid 
pH 2.5 20%(w/v) PEG 6000   4.0 136396 
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The JCSG Core Suite III Composition Table 
 
Solution 
Plate 
number, 
well 
(24-well 
plates) Well Salt Buffer  Precipitant 1 Precipitant 2 Final pH 
Cat. No. 
(Refill-
Hit 
Solution
, 
4 x 12,5 
ml 
tubes) 
1 1,A1 A01  
0.1 M CAPS pH 
10.5 30%(v/v) PEG 400   136401 
2 1,A2 A02  0.1M CHES pH 9.5 40% (v/v) PEG 600   136402 
3 1,A3 A03  0.1M CHES pH 9.5 50% (v/v) PEG 200   136403 
4 1,A4 A04  0.1M CHES pH 9.5 30%(w/v) PEG 3000   136404 
5 1,A5 A05 0.2 M Sodium chloride 0.1M CHES pH 9.5 50%(v/v) PEG 400   136405 
6 1,A6 A06 
0.2 M di-Potassium hydrogen 
phosphate  20%(w/v) PEG 3350   136406 
7 1,B1 A07 
0.2 M di-Sodium hydrogen 
phosphate  20%(w/v) PEG 3350   136407 
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8 1,B2 A08  
0.1 M Bicine pH 
8.5 40%(v/v) MPD  9.0 136408 
9 1,B3 A09  
0.1 M Bicine pH 
8.5 5%(w/v) PEG 6000  9.0 136409 
10 1,B4 A10 0.2 M Ammonium sulfate 
0.1M CAPS pH 
10.5 30% (v/v) PEG 200   136410 
11 1,B5 A11  0.1 M Tris pH 8.5 20%(w/v) PEG 1000   136411 
12 1,B6 A12  0.1 M Tris pH 8.5 
1.0 M di-Ammonium hydrogen 
phosphate   136412 
13 1,C1 B01 0.2 M Magnesium chloride 0.1 M Tris pH 8.5 20%(w/v) PEG 8000   136413 
14 1,C2 B02 0.2 M Lithium sulfate 0.1 M Tris pH 8.5 1.26 M Ammonium sulfate   136414 
15 1,C3 B03 0.01 M Nickel chloride 0.1 M Tris pH 8.5 1.0 M Lithium sulfate   136415 
16 1,C4 B04 
1.6 M Ammonium dihydrogen 
phosphate 
0.08 M Tris-HCl 
pH 8.5 20%(v/v) Glycerol   136416 
17 1,C5 B05 0.2 M Sodium acetate 
0.1 M Tris·HCl pH 
8.5 30%(w/v) PEG 4000   136417 
18 1,C6 B06 1.0 M Sodium citrate 
0.1 M Imidazole 
pH 8.0    136418 
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19 1,D1 B07 0.2 M Magnesium chloride 
0.1 M Imidazole 
pH 8.0 15%(v/v) Ethanol   136419 
20 1,D2 B08 0.2 M Lithium sulfate 
0.1 M Imidazole 
pH 8.0 10%(w/v) PEG 3000   136420 
21 1,D3 B09  0.1 M Tris pH 8.5 40%(v/v) MPD  8.0 136421 
22 1,D4 B10  0.1 M Tris pH 8.5 2.4 M Ammonium sulfate  8.0 136422 
23 1,D5 B11 
0.2 M di-Ammonium hydrogen 
phosphate  20%(w/v) PEG 3350   136423 
24 1,D6 B12 0.2 M Sodium chloride 
0.1 M HEPES pH 
7.5 30%(v/v) PEG 400   136424 
25 2,A1 C01 0.05 M Calcium acetate 
0.1M Imidazole pH 
8.0 35%(v/v) 2-Ethoxyethanol   136425 
26 2,A2 C02 0.2 M tri-Sodium citrate 
0.1 M HEPES pH 
7.5  10%(v/v) Isopropanol   136426 
27 2,A3 C03 0.1 M Sodium chloride 
0.1 M HEPES pH 
7.5 1.6 M Ammonium sulfate   136427 
28 2,A4 C04 0.18 M Magnesium chloride 
0.09 M Sodium 
HEPES pH 7.5 10%(v/v) Glycerol 27%(v/v) Isopropanol  136428 
29 2,A5 C05 1.4 M tri-Sodium citrate 
0.1 M Sodium 
HEPES pH 7.5    136429 
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30 2,A6 C06 0.2 M Calcium chloride 
0.1 M Sodium 
HEPES pH 7.5 28%(v/v) PEG 400   136430 
31 2,B1 C07 0.2 M Magnesium chloride 
0.1 M Sodium 
HEPES pH 7.5 30%(v/v) Isopropanol   136431 
32 2,B2 C08  
0.1M Imidazole pH 
8.0 40% (v/v) PEG 400   136432 
33 2,B3 C09 10% (v/v) Glycerol 
0.1 M HEPES pH 
7.5 5% (w/v) PEG 3000 30% (v/v) PEG 400  136433 
34 2,B4 C10 0.2 M Sodium chloride 0.1 M Tris pH 7.0 1.0 M Sodium citrate   136434 
35 2,B5 C11  0.1 M Tris pH 7.0 15%(v/v) Ethanol   136435 
36 2,B6 C12 0.2 M Sodium chloride 0.1 M Tris pH 7.0 35%(v/v) MPD   136436 
37 2,C1 D01 0.2 M Sodium chloride 
0.1M Imidazole pH 
8.0 1.0 M Potassium/Sodium tartrate   136437 
38 2,C2 D02  
0.1 M HEPES pH 
6.5 40%(v/v) MPD  7.0 136438 
39 2,C3 D03  
0.1 M HEPES pH 
6.5 20%(v/v) MPD  7.0 136439 
40 2,C4 D04  
1.0 M Imidazole 
pH 7.0    136440 
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41 2,C5 D05 0.4 M Potassium/Sodium tartrate     136441 
42 2,C6 D06  
0.1 M HEPES pH 
6.5 2.4 M Ammonium sulfate  7.0 136442 
43 2,D1 D07 1.0 M Lithium chloride 
0.1 M HEPES pH 
7.0 20%(w/v) PEG 6000  7.0 136443 
44 2,D2 D08  
0.1 M HEPES pH 
6.5 5%(w/v) PEG 6000  7.0 136444 
45 2,D3 D09  
0.1 M Sodium 
cacodylate pH 6.5 35%(v/v) 2-Ethoxyethanol   136445 
46 2,D4 D10  0.1 M Tris pH 7.0 50% (v/v) PEG 200   136446 
47 2,D5 D11 0.2 M Sodium chloride 
0.1 M 
Sodium/Potassium 
phosphate pH 6.2 35% (v/v) 2-Ethoxyethanol   136447 
48 2,D6 D12 1.0 M Sodium citrate 
0.1 M Sodium 
cacodylate pH 6.5    136448 
49 3,A1 E01  
0.1 M Sodium 
cacodylate pH 6.5 1.26 M Ammonium sulfate   136449 
50 3,A2 E02 0.01 M Cobalt chloride 0.1 M MES pH 6.5 1.8 M Ammonium sulfate   136450 
51 3,A3 E03  0.1 M MES pH 6.5 1.6 M Ammonium sulfate 10%(v/v) 1,4-Dioxane  136451 
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52 3,A4 E04  0.1 M MES pH 6.5 1.6 M Magnesium sulfate   136452 
53 3,A5 E05 0.16 M Calcium acetate 
0.08 M Sodium 
cacodylate pH 6.5 14.4%(w/v) PEG 8000 20%(v/v) Glycerol  136453 
54 3,A6 E06 0.18 M Magnesium acetate 
0.09 M Sodium 
cacodylate pH 6.5 27% (v/v) MPD 10% (v/v) Glycerol  136454 
55 3,B1 E07 0.16 M Magnesium acetate 
0.08 M Sodium 
cacodylate pH 6.5 16%(w/v) PEG 8000 20%(v/v) Glycerol  136455 
56 3,B2 E08 0.2 M Calcium acetate 
0.1 M Sodium 
cacodylate pH 6.5 18%(w/v) PEG 8000   136456 
57 3,B3 E09 0.2 M Sodium acetate 
0.1 M Sodium 
cacodylate pH 6.5 30%(w/v) PEG 8000   136457 
58 3,B4 E10  
0.1 M Imidazole 
pH 6.5 1.0 M Sodium acetate   136458 
59 3,B5 E11 0.2 M Magnesium acetate 
0.1 M Sodium 
cacodylate pH 6.5 30%(v/v) MPD   136459 
60 3,B6 E12  
0.1 M Sodium 
cacodylate pH 6.5 1.4 M Sodium acetate   136460 
61 3,C1 F01  0.1M MES pH 6.0 40%(v/v) PEG 400 5% (w/v) PEG 3000  136461 
62 3,C2 F02  
0.1M Sodium 
citrate pH 5.5 35%(v/v) 2-Ethoxyethanol   136462 
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63 3,C3 F03  
0.1 M 
Sodium/Potassium 
phosphate pH 6.2 35%(v/v) MPD   136463 
64 3,C4 F04  
0.1 M 
Sodium/Potassium 
phosphate pH 6.2 2.5 M Sodium chloride   136464 
65 3,C5 F05 0.2 M Calcium acetate 0.1 M MES pH 6.0 10%(v/v) Isopropanol   136465 
66 3,C6 F06 0.2 M Zinc acetate 0.1 M MES pH 6.0 10% (w/v) PEG 8000   136466 
67 3,D1 F07  0.1 M MES pH 6.0 3.2 M Ammonium sulfate   136467 
68 3,D2 F08  0.1 M MES pH 5.0 2.4 M Ammonium sulfate  6.0 136468 
69 3,D3 F09  0.1 M MES pH 5.0 0.8 M Ammonium sulfate  6.0 136469 
70 3,D4 F10 0.2 M Potassium/Sodium tartrate 
0.1 M Sodium 
citrate pH 5.6 2.0 M Ammonium sulfate   136470 
71 3,D5 F11 0.17 M Ammonium acetate 
0.085 M Sodium 
citrate pH 5.6 25.5%(w/v) PEG 4000 15%(v/v) Glycerol  136471 
72 3,D6 F12  
0.1 M Sodium 
citrate pH 5.6 
1.0 M Ammonium dihydrogen 
phosphate   136472 
73 4,A1 G01  
0.1 M Sodium 
citrate pH 5.5 2.0 M Ammonium sulfate   136473 
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74 4,A2 G02  
0.1M Sodium 
acetate pH 4.5 40% (v/v) PEG 400   136474 
75 4,A3 G03  0.1M Tris pH 7.0 40% (v/v) PEG 300 5% (w/v) PEG 1000  136475 
76 4,A4 G04  
0.1M Phosphate-
citrate pH 4.2 40%(v/v) PEG 600   136476 
77 4,A5 G05 0.2 M Calcium chloride  20%(w/v) PEG 3350   136477 
78 4,A6 G06  
0.1 M Sodium 
acetate pH 5.0 40%(v/v) MPD  5.0 136478 
79 4,B1 G07  
0.1 M Citric Acid 
pH 5.0 1.0 M Lithium chloride  5.0 136479 
80 4,B2 G08  
0.1 M Citric Acid 
pH 4.0 30%(w/v) PEG 6000  5.0 136480 
81 4,B3 G09  
0.04 M Potassium 
dihydrogen 
phosphate 16%(w/v) PEG 8000 20%(v/v) Glycerol  136481 
82 4,B4 G10 0.1 M Cadmium chloride 
0.1 M Sodium 
acetate pH 4.6 30%(v/v) PEG 400   136482 
83 4,B5 G11 0.2 M Sodium chloride 
0.1 M Sodium 
acetate pH 4.6 30%(v/v) MPD   136483 
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84 4,B6 G12 2.0 M Sodium chloride 
0.1 M Sodium 
acetate pH 4.6    136484 
85 4,C1 H01 2.0 M Sodium formate 
0.1 M Sodium 
acetate pH 4.6    136485 
86 4,C2 H02 0.2 M Calcium chloride 
0.1 M Sodium 
acetate pH 4.6 20%(v/v) Isopropanol   136486 
87 4,C3 H03 0.2 M Lithium sulfate 
0.1 M Sodium 
acetate pH 4.5 2.5 M Sodium chloride   136487 
88 4,C4 H04  
0.1 M Sodium 
acetate pH 4.5 20%(v/v) Butanediol   136488 
89 4,C5 H05 0.2 M Sodium chloride 
0.1 M Sodium 
acetate pH 4.5 1.26 M Ammonium sulfate   136489 
90 4,C6 H06  
0.26 M Ammonium 
dihydrogen 
phosphate 35%(v/v) Glycerol   136490 
91 4,D1 H07  
0.1 M Citric Acid 
pH 2.5 40%(v/v) MPD  4.0 136491 
92 4,D2 H08  
0.1 M Citric Acid 
pH 3.5 2.4 M Ammonium sulfate  4.0 136492 
93 4,D3 H09  
0.1 M Citric Acid 
pH 3.5 1.6 M Ammonium sulfate  4.0 136493 
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94 4,D4 H10 2.0 M Sodium chloride  10%(w/v) PEG 6000   136494 
95 4,D5 H11 0.2 M Ammonium sulfate  30%(w/v) PEG 4000   136495 
96 4,D6 H12 0.2 M Ammonium sulfate  30%(w/v) PEG 8000   136496 
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The JCSG Core Suite IV Composition Table 
 
          
Solution 
Plate 
number, 
well (24-
well 
plates) 
Well 
(96 well 
plates) Salt Buffer  Precipitant 1 
Precipitant 
2 
Precipitant 
3 
Final 
pH 
Cat. No. 
(Refill-
Hit 
Solution
, 
4 x 12,5 
ml 
tubes) 
1 1,A1 A01 0.2 M Lithium sulfate 
0.1 M CAPS pH 
10.5 2.0 M Ammonium sulfate    136501 
2 1,A2 A02 0.2 M Lithium sulfate 
0.1 M Glycine pH 
10.5 
1.2 M Sodium dihydrogen 
phosphate/0.8 M di-Potassium 
hydrogen phosphate    136502 
3 1,A3 A03  
0.1M CAPS pH 
10.5 40%(v/v) MPD    136503 
4 1,A4 A04  
0.1 M CHES pH 
9.5 10%(w/v) PEG 3000    136504 
5 1,A5 A05 0.2 M Lithium sulfate 
0.1 M CHES pH 
9.5 1.0 M Sodium/Potassium tartrate    136505 
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6 1,A6 A06  
0.1 M CHES pH 
9.5 30%(v/v) PEG 400    136506 
7 1,B1 A07  
0.1 M CHES pH 
9.5 15%(v/v) Ethanol    136507 
8 1,B2 A08 0.2 M Sodium citrate 
0.1M CHES pH 
9.5 40%(v/v) PEG 300    136508 
9 1,B3 A09  
0.1M CHES pH 
9.5 40%(v/v) MPD    136509 
10 1,B4 A10  
0.1 M Bicine pH 
9.0 1.6 M Ammonium sulfate   9.0 136510 
11 1,B5 A11  
0.1 M Bicine pH 
9.0 0.8 M Ammonium sulfate   9.0 136511 
12 1,B6 A12  
0.1 M Bicine pH 
9.0 2.4 M Ammonium sulfate   9.0 136512 
13 1,C1 B01  
0.1 M Bicine pH 
8.5 10%(w/v) PEG 6000   9.0 136513 
14 1,C2 B02  
0.1 M Bicine pH 
9.0 2.4 M Ammonium sulfate    136514 
15 1,C3 B03  
0.1 M Bicine pH 
8.5 30%(w/v) PEG 6000   9.0 136515 
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16 1,C4 B04  
0.1 M Bicine pH 
8.5 65%(v/v) MPD   9.0 136516 
17 1,C5 B05  
0.1 M Bicine pH 
9.0 2.0 M Magnesium chloride    136517 
18 1,C6 B06  0.1 M Tris pH 8.5 10%(v/v) Isopropanol    136518 
19 1,D1 B07 0.2 M Magnesium chloride 0.1M Tris pH 8.5 50%(v/v) Ethylene glycol    136519 
20 1,D2 B08 0.2 M Magnesium chloride 0.1M Tris pH 8.5 25%(v/v) 1,2-Propanediol 
10%(v/v) 
Glycerol   136520 
21 1,D3 B09 0.2 M Magnesium chloride 
0.1 M Tris·HCl pH 
8.5 30%(w/v) PEG 4000    136521 
22 1,D4 B10 0.2 M Sodium citrate 
0.1 M Tris·HCl pH 
8.5 30%(v/v) PEG 400    136522 
23 1,D5 B11 0.2 M Lithium sulfate 
0.1 M Tris·HCl pH 
8.5 30%(w/v) PEG 4000    136523 
24 1,D6 B12 0.2 M Ammonium acetate 
0.1 M Tris-HCl pH 
8.5 30%(v/v) Isopropanol    136524 
25 2,A1 C01  0.1 M Tris pH 8.5 1.5 M Ammonium sulfate 
12%(v/v) 
Glycerol   136525 
26 2,A2 C02 0.18 M tri-Sodium citrate 
0.09 M TRIS.HCl 
pH 8.5 27 %(v/v) PEG 400 
10 %(v/v) 
Glycerol   136526 
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27 2,A3 C03 0.17 M Sodium acetate 
0.085 M Tris·HCl 
pH 8.5 25.5%(w/v) PEG 4000 
15%(v/v) 
Glycerol   136527 
28 2,A4 C04  
0.1 M Imidazole 
pH 8.0 10%(v/v) Isopropanol    136528 
29 2,A5 C05 0.2 M Zinc acetate 
0.1 M Imidazole 
pH 8.0 2.5 M Sodium chloride    136529 
30 2,A6 C06  
0.1 M Imidazole 
pH 8.0 2.5 M Sodium chloride    136530 
31 2,B1 C07  
0.1 M Imidazole 
pH 8.0 10%(w/v) PEG 8000    136531 
32 2,B2 C08 0.2 M Sodium chloride 
0.1 M Imidazole 
pH 8.0 1.0 M di-Ammonium phosphate    136532 
33 2,B3 C09  0.1 M Tris pH 8.5 1.6 M Ammonium sulfate   8.0 136533 
34 2,B4 C10  0.1 M Tris pH 8.5 5%(w/v) PEG 6000   8.0 136534 
35 2,B5 C11  0.1 M Tris pH 8.5 65%(v/v) MPD   8.0 136535 
36 2,B6 C12 1.0 M Lithium chloride 0.1 M Tris pH 8.5 10%(w/v) PEG 6000   8.0 136536 
37 2,C1 D01  0.1 M Tris pH 8.0 3.2 M Ammonium sulfate    136537 
38 2,C2 D02  
0.1 M HEPES pH 
7.5 1.26 M Ammonium sulfate    136538 
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39 2,C3 D03 0.2 M Sodium chloride 
0.1 M HEPES pH 
7.5 35%(v/v) MPD    136539 
40 2,C4 D04  
0.1M HEPES pH 
7.5 50%(v/v) PEG 200    136540 
41 2,C5 D05  
0.1 M HEPES pH 
7.5 1.5 M Lithium sulfate    136541 
42 2,C6 D06  
0.1 M HEPES pH 
7.5 4.3 M Sodium chloride    136542 
43 2,D1 D07 0.2 M Sodium citrate 
0.1 M HEPES pH 
7.5 30%(v/v) MPD    136543 
44 2,D2 D08  
0.1 M HEPES pH 
7.5 20%(w/v) PEG 10000 
8%(v/v) 
Ethylene 
glycol   136544 
45 2,D3 D09  
0.09 M HEPES pH 
7.5 1.26 M tri-Sodium citrate 
10%(v/v) 
Glycerol   136545 
46 2,D4 D10 1.7 M Ammonium sulfate 
0.085 M HEPES 
pH 7.5 1.7%(v/v) PEG 400 
15%(v/v) 
Glycerol   136546 
47 2,D5 D11 0.05 M Lithium sulfate 
0.1M HEPES pH 
7.5 30%(v/v) PEG 600 
10%(v/v) 
Glycerol    136547 
48 2,D6 D12  
0.1M HEPES pH 
7.5 30%(v/v) 1,2-Propanediol 
20%(v/v) 
PEG 400   136548 
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49 3,A1 E01 0.2 M Ammonium sulfate 0.1M Tris pH 7.0 25%(v/v) 1,2-Propanediol 
10%(v/v) 
Glycerol   136549 
50 3,A2 E02  
0.1M HEPES pH 
7.5 5%(w/v) PEG 3000 
40%(v/v) 
Ethylene 
glycol   136550 
51 3,A3 E03 0.2 M Ammonium sulfate 0.1M Tris pH 7.0 40%(v/v) MPD    136551 
52 3,A4 E04   4.0 M Sodium formate    136552 
53 3,A5 E05   3.6 M Sodium formate 
10%(v/v) 
Glycerol   136553 
54 3,A6 E06 0.2 M Calcium acetate 
0.1M HEPES pH 
7.5 40%(v/v) PEG 400    136554 
55 3,B1 E07 0.2 M Sodium chloride 0.1 M Tris pH 7.0 30%(w/v) PEG 3000    136555 
56 3,B2 E08 0.2 M Lithium sulfate 0.1 M Tris pH 7.0 1.0 M Sodium/Potassium tartrate    136556 
57 3,B3 E09 0.2 M Calcium acetate 
0.1M Sodium 
cacodylate pH 6.5 40%(v/v) PEG 600    136557 
58 3,B4 E10  
0.1 M HEPES pH 
6.5 0.8 M Ammonium sulfate   7.0 136558 
59 3,B5 E11  
0.1 M HEPES pH 
7.0 3.2 M Ammonium sulfate    136559 
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60 3,B6 E12  
0.1 M HEPES pH 
6.5 30%(w/v) PEG 6000   7.0 136560 
61 3,C1 F01 1.0 M Lithium chloride 
0.1 M HEPES pH 
7.0     136561 
62 3,C2 F02 1 M Sodium chloride 
0.1M Sodium 
cacodylate pH 6.5 30%(v/v) PEG 600 
10%(v/v) 
Glycerol   136562 
63 3,C3 F03 0.2 M Zinc acetate 
0.1 M Sodium 
cacodylate pH 6.5 10%(v/v) Isopropanol    136563 
64 3,C4 F04 0.2 M Calcium acetate 
0.1M Sodium 
cacodylate pH 6.5 45%(v/v) Glycerol    136564 
65 3,C5 F05  
0.1 M HEPES pH 
7.0  30%(v/v) Jeffamine M-600   7.0 136565 
66 3,C6 F06 
0.1 M Sodium dihydrogen 
phosphate/ 0.1 M potassium 
dihydrogen phosphate 0.1 M MES pH 6.5 2.0 M Sodium chloride    136566 
67 3,D1 F07 0.16 M Zinc acetate 
0.08 M Sodium 
cacodylate pH 6.5 14.4%(w/v) PEG 8000 
20%(v/v) 
Glycerol   136567 
68 3,D2 F08  
0.1M Sodium 
citrate pH 5.5 30%(v/v) 1,2-Propanediol 
20%(v/v) 
MPD   136568 
69 3,D3 F09 0.2 M Zinc acetate  20%(w/v) PEG 3350    136569 
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70 3,D4 F10  
0.1M Sodium 
citrate pH 5.5 5%(w/v) PEG 1000 
35%(v/v) 
Isopropanol   136570 
71 3,D5 F11  0.1M MES pH 6.0 30%(v/v) PEG 600 
5%(w/v) 
PEG 1000 
10%(v/v) 
Glycerol  136571 
72 3,D6 F12  
0.1M Sodium 
citrate pH 5.5 40%(v/v) MPD    136572 
73 4,A1 G01 0.2 M Zinc acetate 
0.1M Imidazole 
pH 8.0 35%(v/v) Isopropanol    136573 
74 4,A2 G02  0.1 M MES pH 6.0 1.0 M Sodium/Potassium tartrate    136574 
75 4,A3 G03 0.2 M Lithium sulfate 0.1 M MES pH 6.0 20%(v/v) Butanediol    136575 
76 4,A4 G04 0.2 M Zinc acetate 0.1 M MES pH 6.0 15%(v/v) Ethanol    136576 
77 4,A5 G05  0.1 M MES pH 5.0 1.6 M Ammonium sulfate   6.0 136577 
78 4,A6 G06  0.1 M MES pH 5.0 30%(w/v) PEG 6000   6.0 136578 
79 4,B1 G07 0.2 M Zinc acetate 
0.1M Imidazole 
pH 8.0 40%(v/v) PEG 300    136579 
80 4,B2 G08 0.2 M Ammonium acetate 
0.1 M Sodium 
citrate pH 5.6 30%(v/v) MPD    136580 
81 4,B3 G09 0.01 M Iron(II)chloride 
0.1 M Sodium 
citrate pH 5.6 10%(v/v) Jeffamine M-600    136581 
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82 4,B4 G10 
0.7 M Ammonium dihydrogen 
phosphate 
0.07 M Sodium 
citrate pH 5.6 30%(v/v) Glycerol    136582 
83 4,B5 G11 0.2 M Lithium sulfate 
0.1 M Sodium 
citrate pH 5.5 15%(v/v) Ethanol    136583 
84 4,B6 G12 0.05 M Calcium acetate 
0.1M Sodium 
acetate pH 4.5 40%(v/v) 1,2-Propanediol    136584 
85 4,C1 H01  
0.1M Sodium 
acetate pH 4.5 35%(v/v) Isopropanol    136585 
86 4,C2 H02 0.2 M Ammonium acetate 
0.1 M Sodium 
acetate pH 4.6 30%(w/v) PEG 4000    136586 
87 4,C3 H03 0.17 M Ammonium acetate 
0.085 M Sodium 
acetate pH 4.6 25.5%(w/v) PEG 4000 
15%(v/v) 
Glycerol   136587 
88 4,C4 H04 0.2 M Zinc acetate 
0.1 M Sodium 
acetate pH 4.5 20%(w/v) PEG 1000    136588 
89 4,C5 H05  
0.1 M Sodium 
acetate pH 4.5 1.0 M di-Ammonium phosphate    136589 
90 4,C6 H06  
0.1 M Sodium 
acetate pH 4.5 
0.8 M Sodium dihydrogen 
phosphate/1.2 M di-Potassium 
hydrogen phosphate    136590 
  
Page 108 of 117 
 
91 4,D1 H07 0.2 M Ammonium sulfate 
0.1M Phosphate-
citrate pH 4.2  
40%(v/v) 
Ethylene 
glycol   136591 
92 4,D2 H08   10%(v/v) Ethanol 
1.5 M 
Sodium 
chloride   136592 
93 4,D3 H09   1.5 M Ammonium sulfate 
25%(v/v) 
Glycerol   136593 
94 4,D4 H10  
0.1 M Phosphate-
citrate pH 4.2 
1.6 M Sodium dihydrogen 
phosphate/0.4 M di-Potassium 
hydrogen phosphate    136594 
95 4,D5 H11  
0.1 M Citric Acid 
pH 2.5 30%(w/v) PEG 6000   4.0 136595 
96 4,D6 H12 1.0 M Lithium chloride 0.1 M Citric Acid 30%(w/v) PEG 6000   4.0 136596 
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Appendix B  
Crystallization Screening Tables 
Crystals were ranked on a scale from 1-9 based on the following descriptions (table XX). 
Table XX: Descriptions of each rank used to describe crystals 
Ranking Description 
1 Clear Drop 
2 Phase Separation 
3 Regular Granular Precipitate  
4 Birefringent Precipitate or Microcrystals 
5 Posettes or Spherulites 
6 Needles (1D Growth) 
7 Plates (2D Growth) 
8 Single Crystal (3D Growth <0.2mm) 
9 Single Crystal (3D Growth >0.2mm) 
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Lysozyme 
Self-prepared conditions 
Table XX1: Ranking results of lysozyme plate containing custom made conditions. Only the middle well of the first row was used for these conditions. 
  1 
a 9 
b 9 
c 8 
d 9 
e 9 
f 9 
g 9 
h 9 
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Testing kit (NeXtal DWBlock JCSG Core I Suite – produced by Qiagen) 
Table XX1: Ranking results of lysozyme plate containing conditions from kit 1. Only the middle wells of each row were used.  
  1 2 3 4 5 6 7 8 9 10 11 12 
a 6 6 5 7 1 1 6 9 6 1 4 7 
b 8 6 8 6 1 5 6 2 6 8 4 6 
c 6 7 1 6 7 7 5 3 2 3 1 4 
d 6 6 1 1 1 6 9 1 1 1 1 6 
e 5 1 5 1 6 3 7 1 1 1 5 1 
f 6 1 1 7 1 1 1 1 7 1 1 1 
g 7 6 6 9 6 6 1 1 1 6 8 1 
h 6 6 1 3 1 1 6 8 6 8 8 8 
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OP-145 
Attempt 1 
Kit 1 (NeXtal DWBlock JCSG Core I Suite – produced by Qiagen) 
Table XX1: Ranking results of OP-145 plate containing conditions from kit 1. All wells of all rows were used, and wells are written in italics (1: Peptide alone, 2: 
Peptide and LDAO, 3: Peptide and DPC). 
 1 2 3 4 5 6 7 8 9 10 11 12 
  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
a 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
b 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c 1 1 1 1 1 1 1 1 6 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
d 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
e 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
f 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 6 6 7 4 6 6 
g 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
h 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
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Kit 2 (NeXtal DWBlock JCSG Core II Suite – produced by Qiagen) 
Table XX1: Ranking results of OP-145 plate containing conditions from kit 2. All wells of all rows were used, and wells are written in italics (1: Peptide alone, 2: 
Peptide and LDAO, 3: Peptide and DPC). 
 1 2 3 4 5 6 7 8 9 10 11 12 
  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
a 3 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 
b 1 1 1 4 6 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c 1 1 1 1 1 1 1 1 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1  7 1 1 1 1 1 1 1 1 1 1 1 
d 1 1 1 1 1 1 1 1 3 7 7 7 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 
e 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
f 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 8 1 1 
g 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 8 8 8 1 1 1 1 1 1 1 1 1 
h 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 1 1 
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Kit 3 (NeXtal DWBlock JCSG Core III Suite – produced by Qiagen) 
Table XX1: Ranking results of OP-145 plate containing conditions from kit 3. All wells of all rows were used, and wells are written in italics (1: Peptide alone, 2: 
Peptide and LDAO, 3: Peptide and DPC). 
 1 2 3 4 5 6 7 8 9 10 11 12 
  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
a 3 3 3 1 1 1 1 1 1 1 1 1 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
b 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
c 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
d 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 
e 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
f 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
g 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
h 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 
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Kit 4(NeXtal DWBlock JCSG Core IV Suite – produced by Qiagen) 
Table XX1: Ranking results of OP-145 plate containing conditions from kit 4. All wells of all rows were used, and wells are written in italics (1: Peptide alone, 2: 
Peptide and LDAO, 3: Peptide and DPC). 
 1 2 3 4 5 6 7 8 9 10 11 12 
  1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
a 3 3 3 1 1 1 1 6 1 1 1 1 1 1 1 1 6 6 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 
b 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 6 1 1 1 1 1 5 1 1 6 1 6 1 1 1 1 6 1 1 1 1 
c 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
d 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 6 6 1 1 1 1 1 1 1 1 1 1 3 1 1 1 
e 1 1 6 1 1 1 1 1 1 6 1 4 1 1 3 1 1 1 1 1 6 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 
f 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 6 6 1 1 3 1 1 1 1 1 1 1 1 
g 1 1 1 1 1 1 1 3 1 1 1 1 1 1 3 6 1 6 1 1 1 1 1 1 3 3 3 1 1 1 1 1 1 1 1 1 
h 3* 1 1 1 1 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 3 1 1 1 3 
*Precipitate is black 
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Attempt 2 
Kit 1 (NeXtal DWBlock JCSG Core I Suite – produced by Qiagen) 
Table XX1: Ranking results of lysozyme plate containing conditions from kit 1. Only the middle wells of each row were used.  
  1 2 3 4 5 6 7 8 9 10 11 12 
a 3 1 4 1 6 1 1 1 1 1 1 1 
b 1 1 1 1 1 1 1 1 1 1 1 1 
c 3 1 1 1 1 1 1 1 1 1 1 1 
d 1 1 1 1 1 1 1 4 1 1 1 1 
e 4 1 1 1 1 1 1 1 4 1 1 1 
f 4 4 1 1 1 4 4 4 1 4 4 4 
g 1 1 4 1 1 4 4 1 1 1 1 1 
h 6 1 4 1 1 1 4 1 1 1 1 1 
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Kit 2 (NeXtal DWBlock JCSG Core II Suite – produced by Qiagen) 
Table XX1: Ranking results of lysozyme plate containing conditions from kit 2. Only the middle wells of each row were used.  
  1 2 3 4 5 6 7 8 9 10 11 12 
a 1 1 1 1 1 4 1 1 1 1 1 1 
b 1 4 1 1 1 1 1 1 1 1 1 1 
c 1 1 4 4 1 1 1 1 1 1 3 3 
d 4 1 1 4 1 4 1 1 1 1 1 3 
e 1 1 1 1 1 1 1 4 1 1 1 1 
f 1 4 1 6 1 1 1 1 1 1 1 1 
g 1 6 1 1 1 1 1 3 1 4 1 3 
h 1 4 1 4 1 1 1 1 1 1 1 3 
 
 
 
 
 
 
 
 
 
